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LIST OF ABBREVIATIONS AND ACRONYMS 
 
ABC   : Abacavir 
ACTG                   : AIDS Clinical Trials Group 
ADR   : Adverse Drug Reaction 
AIDS            : Acquired Immunodeficiency Syndrome 
ALC                      : Absolute lymphocyte Count 
ALT                      : Alanine aminotransferase 
ART   : Anti-Retroviral Therapy 
ARV   : Anti-Retroviral 
AST                       : Aspartate aminotransferase 
AZT   : Azidothymidine 
BMI   : Body Mass Index 
CBC                      : Complete Blood Counts 
CD4   : CD4+ T-Lymphocyte (T-lymphocyte bearing CD4 receptor) 
CI                          : (95%) confidence interval  
ddI   : Didanosine 
d4T   : Stavudine 
DRESS  : Drug Rash, Eosinophilia and Systemic Symptoms 
EFV   : Efavirenz 
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FDC                      : Fixed-Dose Combination 
FTC   : Emricitabine 
HAART  : Highly Active Anti-Retroviral Therapy 
HBV   : Hepatitis B Virus 
HCV   : Hepatitis C Virus 
HIV   : Human Immunodeficiency Virus 
IDV   : Indinavir 
IGT                       : Impaired Glucose Tolerance 
IQR                       : Inter-Quartile Range 
IRIS                      : Immune Reconstitution Inflammatory Syndrome 
MTCT  : Mother- to- Child Transmission 
NACO  : National AIDS Control Organization 
NFV   : Nelfinavir 
NNRTI  : Non Nucleoside Reverse Transcriptase Inhibitor 
NRTI   : Nucleoside Reverse Transcriptase Inhibitor 
NtRTI                   : Nucleotide Reverse Transcriptase Inhibitor 
NVP   : Nevirapine 
OI   : Opportunistic Infection 
PI   : Protease Inhibitor 
PLHA  : People Living with HIV/AIDS 
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PPTCT  : Prevention of Parent - to - Child Transmission 
PVL   : Plasma Viral Load 
RIF   : Rifampicin 
SJS   : Stevens-Johnson Syndrome 
STI   : Sexually Transmitted Infections 
TB   : Tuberculosis 
TDF   : Tenofovir 
TEN   : Toxic Epidermal Necrolysis 
3TC   : Lamivudine 
UNAIDS  : United Nations Programme on HIV/AIDS 
VCTC  : Voluntary Counseling and Testing Centre 
WHO  : World Health Organization 
YRG CARE : Y R Gaitonde Centre for AIDS Research and Education 
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                                   INTRODUCTION 
 
 
The battle against the staggering worldwide growth of the HIV pandemic has been 
revolutionalised by the advent of HAART. HAART has resulted in substantial reductions 
in mortality, progression to AIDS, incidence of OIs, and hospitalizations in patients who 
respond to therapy.(1) With rational use of HAART, HIV infection can be transformed 
into a chronic manageable illness like diabetes and hypertension. Pallela et al in a study 
published in 1998, provided evidence of a massive decrease in morbidity and mortality 
associated with HIV infection after the advent of HAART. Mortality rates had decreased 
by 75% (from 35.1 to 8.8 per 100 person-years) between early 1994 and mid-1997, and 
the incidence of AIDS-defining diseases decreased by nearly 73%.(2) Similar efficacy 
was noted by Egger et al in the ART collaboration cohort study.(3) It provided important 
clinical implications for management which were subsequently incorporated in the 
treatment guidelines.  
 
Majority of people infected with HIV reside in the developing world where resources are 
limited. Ensuring universal access to HAART is critical for the survival of patients in 
these settings. This problem has been partly overcome by the programmes and initiatives 
launched by the various health organizations. In the “3 by 5” initiative, launched by 
WHO in 2003, a global target was set to provide three million individuals living in the 
developing world with ART, by 2005. As part of the world AIDS day commemoration in 
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2003, the Government of India (GOI) announced a policy commitment to provide free 
ART to one lakh patients by the year 2007 and 1.8 lakh patients by 2010. This policy 
development was in line with the declaration of the AIDS treatment gap as a global 
public health emergency and the launch of the “3 by 5” initiative by WHO. The national 
ART programme has also been scaled-up with centers providing comprehensive 
HIV/AIDS continuum of prevention, care and treatment services.  
 
Generic FDC of ARV drugs manufactured mostly by Indian pharmaceutical firms have 
given a boost to efforts to improve access to HAART. The advantages of using generic 
fixed combination HAART include: low cost, simplified education and training of 
providers, standard monitoring for toxicity, predictable pattern of resistance, better 
adherence and limited number of drugs to manage with easier organization of support 
groups. 
 
However, there are scarce data on the efficacy and tolerability of antiretroviral therapy in 
Indian population. Pujari et al while studying the effectiveness of generic NVP-based 
HAART in India concluded that there was a significant improvement in CD4 cell counts 
over a period of 2 years with this regimen. The incidence of acute NVP induced ADR 
like drug rash and hepatitis were 6.6% and 3.2% respectively.(4) The lower incidence 
was attributed to adherence to the lead-in-dose of NVP and monitoring of liver function 
tests only when clinically indicated. Kumarasamy et al of YRG CARE centre, Chennai 
identified modification of generic initial HAART regimens in 20% of the patients with 
ADR contributing to nearly 64% of treatment modification.(5)  
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Due to noticeable differences in the demographic profile of the patients, results of studies 
from the West may not be directly applicable to our population. There are reasons to 
believe that response to HAART in our patients may be significantly different from the 
West.  
The factors that could potentially modify the response to HAART in India compared to 
the West include: 
1. Presentation at fairly advanced stages of HIV infection. 
2. High prevalence of Mycobacterium tuberculosis co-infection (Nearly two million of 
the five million HIV infected adults in India are co-infected with TB).(6) 
3. Use of thymidine analogue NRTI and NVP in HAART regimens. 
4. Increased prevalence of malnutrition and IGT (impaired glucose tolerance).  
5. The presence of non-subtype B HIV virus (subtype C).(7) 
 
Hence, the present study was designed to find the incidence and determinants of failure 
of the initial HAART regimen in a cohort of ART naïve south Indian adults.  
 
Optimization of the initial HAART regimen for complete viral suppression and better 
tolerability is paramount for the prognosis of HIV infected patients. In order to choose 
the optimal regimen one should also be fully aware of the concepts of HAART and the 
pharmacology of individual ARV drugs. 
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                       OBJECTIVES  OF  STUDY 
 
 
 
1. To prospectively follow-up a cohort of antiretroviral therapy naïve HIV 
infected South Indian adults started on Highly Active Antiretroviral 
therapy (HAART). 
2. To determine the incidence and determinants of failure of initial HAART 
regimen in these patients. 
3. To determine the incidence and predictors of severe adverse drug 
reactions (ADR) necessitating a change of the HAART regimen in the 
study cohort. 
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Review of Literature 
HIV medicine is a rapidly changing specialty necessitating periodic updating. According 
to UNAIDS,(8) India has 5.7 million people living with HIV - more than any other 
country in the world. Of these, 39% are females and 30% are below the age of 30 years. 
According to estimates, it has been projected that India will suffer 12.3 million AIDS 
deaths during the years 2000-2015. In contrast to the earlier days of the HIV epidemic, a 
diagnosis of HIV infection need no longer be equated with an inevitably fatal disease. 
HAART has emerged the cornerstone of management of patients with HIV infection. The 
appropriate use of potent HAART regimens and other treatment and prophylactic 
interventions are of critical importance in providing each patient the best opportunity to 
live a long and healthy life. 
 
Our main focus in this section will be to discuss the factors that could lead to failure of 
the initial HAART regimen quoting references from published literature in detail and to 
help formulate measures that could minimize the incidence of regimen failure and 
increase the tolerability and effectiveness of HAART. To achieve this one has to be 
aware of the goals of therapy, basic concepts of HAART, exact indications for initiation 
of therapy and pharmacology of the ARV drugs. 
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Pathogenesis: 
HIV targets, infects and incapacitates cells central to host defenses against microbial 
pathogens. There is a relentless and high rate of viral replication, progressive decline in 
CD4+ T cells (‘helper’ T cells) with profound immunodeficiency and subsequently 
general decline in health leading to opportunistic infections and cancers. 
 
The following are the goals of antiretroviral therapy: 
1. Maximum and durable suppression of viral replication. 
2. Preservation and/or restoration of immune functions. 
3. Reduction of HIV related morbidity and mortality. 
4. Improvement of quality of life.  
Concept of HAART: 
In addition to achieve the above goals, the concept of HAART has also evolved to 
prevent the emergence of drug resistant mutants. HAART regimens have at least three 
active antiretroviral medications. Regimens commonly have a base and a backbone. The 
base is either an NNRTI or a PI *(there may be a second PI given to “boost” the base PI). 
The backbone typically consists of two NRTIs. 
 Note*: PI based regimens frequently use a low dose of Ritonavir to increase (“boost”) 
the drug level and duration of another PI. Ritonavir is an extremely potent inhibitor of PI 
metabolism via the CYP3A4 pathway.  
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Evolution of antiretroviral therapy: 
The evolution of ART began in 1987 with the advent of AZT monotherapy. Fischl et al 
demonstrated that AZT administration decreased mortality and the frequency of 
opportunistic infections in patients with AIDS or AIDS-related complex.(9) Hammer et al 
concluded in his study published in 1997 that addition of another NRTI to AZT 
significantly slowed the progression of HIV infection and was superior to monotherapy. 
(10) The concept of HAART came in 1997 when Gulick et al demonstrated that with 
addition of indinavir (IDV) to a dual nucleoside backbone there was durable virological 
suppression.(11) 
 
Impact of therapy: 
 
Advent of HAART resulted in a dramatic decrease in the morbidity and mortality related 
to HIV infection which has been proven in various studies. A report from HIV clinics in 
eight cities in the United States conducted by the HIV Outpatient Study (HOPS) showed 
that the mortality of patients with a CD4 cell counts below 100cells/µL declined from 
29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in 1997.(2) There was also 
decline in the three major OIs Pneumocystis pneumonia, Mycobacterium avium 
bacteremia, and disseminated cytomegalovirus infections; these declined during this 
period from 21.9 to 2.3 per 100 person-years. The EuroSIDA cohort showed a dramatic 
decline in mortality from 23.3 per 100 person-years in 1994 to 4.1 per 100 person-years 
in 1998.(12) 
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Challenges to antiretroviral therapy 
The new concerns that arose in due course of time to continuation of a successful 
HAART regimen include: 
1. Cost of therapy. 
2. Side effects of medications. 
3. Drug interactions. 
4. Difficulties in adhering to complicated regimens. 
5. Emergence of drug resistance 
6. Variations in individual response.  
Adherence, drug toxicities and emergence of resistance in clinical practice are major 
issues leading eventually to regimen failure. These will be mentioned in detail in the 
sections below. 
 
Initiation and monitoring of patients on HAART 
Indications for antiretroviral therapy: 
The major factors used to indicate a need for initiation of ART in patients are the 
presence of symptomatic HIV disease and the CD4 cell counts. There is strong evidence 
supporting the use of the CD4 cell counts as the major determinant in initiating therapy. 
(2,13) The plasma HIV RNA level remains an independent predictor of clinical outcome 
in patients who do not receive HAART and is one of the best available guides for 
monitoring the effectiveness of HAART.(14,15) 
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Several observations contribute to the dilemma about when to start treatment in 
asymptomatic individuals. Antiretroviral therapy with a CD4 cell counts > 200/µL has 
either no, or only a modest benefit in some studies, while others shows substantial 
benefits.(16) 
 Although the rate of disease progression among HIV-infected individuals varies greatly, 
whenever possible, HAART should be initiated before the CD4 threshold of 200/µL has 
been reached. Patients with CD4 cell counts < 200/µL are at greatly increased risk of 
serious life-threatening OIs, and immune reconstitution illness is largely limited to 
individuals who initiate therapy with very low CD4 cell counts and very high plasma 
viral loads.(17-19) Individuals with CD4 cell counts > 350/µL, on the other hand, have a 
low risk of clinical progression at 3 years, and concerns about the impact of ARV drugs 
on quality of life, adherence to regimens, risks of serious adverse effects of the drugs, and 
emergence of viral resistance that will limit future treatment options generally outweigh 
the benefits of durable viral suppression. No study has shown convincing evidence of 
benefit for treatment initiated when the CD4 count is > 350/µL. 
 In patients with a CD4 cell counts between 200 and 350/µL, clinicians must consider the 
potential risks and benefits of treatment since current drugs have substantial short- and 
long-term toxicity and carry risk of emergence of drug resistance if inadvertently used. 
Viral load is also an independent prognostic indicator. Extremely high viral loads 
(>100,000 copies/mL) correlate with a poor prognosis and is an indicator for initiation of 
treatment. 
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The following are the recommendations for initiating ART in adults with HIV infection 
(WHO 2003) 
If CD4 cell testing available: 
WHO clinical stage IV disease. 
WHO clinical stage III with consideration of using CD4 cell counts < 350/µL to assist 
decision making. 
WHO clinical stage I or II disease with CD4 cell counts less than or equal to 200/µL 
If CD4 testing not available: 
WHO clinical stage III and IV disease 
WHO stage II disease with absolute lymphocyte count (ALC) less than or equal to 1200 
cells/µL. 
In addition to them, patients with acute HIV infection may be candidates for ART as they 
can decrease severity of acute disease and reduce disease progression/transmission rates. 
Pregnant women should also generally be treated with ART to reduce the risk of vertical 
transmission (PPTCT)  
Evaluation prior to initiation of ART 
 
1. Confirmation of diagnosis: A prerequisite prior to HAART initiation. It is also needed 
to rule out HIV-2 infection as NNRTIs have no activity against HIV-2.(20) 
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2. History and physical examination: should focus on symptomatic HIV disease for 
staging of infection, evidence of OI that could potentially flare with the immune 
reconstitution seen after starting HAART. 
3. As adherence is probably the most important factor in determining the success of an 
initial HAART regimen, a detailed psychosocial evaluation is required as these factors 
can have a strong influence on patient adherence. 
Psychosocial evaluation —Issues to consider include: 
1. Substance abuse: Substance abuse contributes to a disordered lifestyle and may lead to 
inadvertent missed medications doses.  
2. Psychiatric disorders: Depression, bipolar disorder, and other psychiatric disorders 
may interfere with a patient's ability or desire to adhere to a medication regimen.  
3. Housing: Patients with an unstable housing situation (such as the homeless) may have 
difficulties keeping medications available, remembering to take medications, and dealing 
with side effects such as diarrhea.  
4. Ability to afford medications: Depending on where patients live, their economic 
resources, and their insurance, affordability of medications may be a major constraint in 
some cases.  
5. Work schedule: Patients with irregular work schedules may have difficulty taking 
medications at prescribed times.  
6. Family support and friends.  
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All patients being considered for ART should have the following laboratory tests:       
 1. Complete blood count with differential.  
2. Electrolytes, serum creatinine, and glucose.  
3. Liver function tests. 
4. A lipid profile including triglycerides.  
5. Serologic tests for hepatitis B and hepatitis C virus.  
Measurement of the HIV plasma viral load and CD4 cell counts (preferably when patient 
not ill) 
ANTI-RETROVIRAL REGIMENS: 
Main classes of drugs used: 
• Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs)  
• Nonnucleoside reverse transcriptase inhibitors (NNRTIs)  
• Protease inhibitors (PIs)  
• Nucleotide analogue reverse transcriptase inhibitors (NtRTI like tenofovir) 
• Fusion inhibitors 
Fusion inhibitors are not currently used as part of initial ART regimens. 
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Pill burden - HAART regimens, particularly those that include PIs, frequently require 
patients to ingest many large pills with each dose. Newer drugs, regimens, and pill 
formulations are reducing this burden. 
Drug regimens:   
Major clinical trials of HAART are still underway. Four drug regimens and sequential 
three drug regimens could prove to be more potent and tolerable  
PI plus NNRTI based regimens: 
ACTG 384 ( AIDS Control Trial Groups )— This randomized trial compared a four- 
drug regimens containing (NFV + EFV + 2 NRTIs) versus three- drug regimens (NFV or 
EFV with 2 NRTIs) comparing NFV with EFV. The NRTI backbone of (AZT + 3TC) 
was compared to (d4T + ddI). The conclusions of the trial were: 
a) There were no differences between the four-drug and sequential three drug regimens in 
the primary end points. 
b) EFV was better than NFV when combined with AZT + 3TC.  
Hence, it was concluded that AZT + 3TC + EFV was the preferred initial HAART 
regimen.(21) 
Comparison of NNRTI based regimens: 
In the 2NN study, Van Leth et al concluded that HAART with either NVP or EFV 
combined with a standard dual nucleoside backbone showed similar efficacy with some 
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noticeable differences in safety profile. The NVP once daily group had significantly 
higher incidence of side effects. The combination of both EFV and NVP was neither 
effective nor tolerated in the study population.(22) 
Tenofovir based regimens 
Tenofovir disoproxil fumarate (TDF), a NtRTI is a potent agent with a long intracellular 
half-life that allows for once-daily dosing. It has been well tolerated in clinical trials, 
without evidence of the mitochondrial toxicity that has been associated with long-term 
treatment of some of the NRTIs. Because of its demonstrated efficacy and favorable 
safety profile, TDF has quickly become a favored nucleoside component of ARV 
regimens for both treatment-naive and -experienced patients.(23) 
Antiretroviral combinations to avoid — certain combinations of ARV medications that 
might appear to fit into a standard pattern should be avoided either because of toxicity or 
lack of efficacy: 
• AZT and d4T should not be used together as their actions are antagonistic.  
• 3TC and FTC are similar drugs and should not be used together.  
• The use of EFV and NVP together produces more side effects and is less    
efficacious than either drug alone (2NN study) 
• Because of concern about the long-term toxicity of ddI with d4T including 
peripheral neuropathy, pancreatitis and lipodystrophy this combination is less desirable. 
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Laboratory monitoring 
• CBC with differential  
• Electrolytes  
• Serum creatinine and blood urea nitrogen (BUN)  
• Liver transaminases  
Patients on NVP should have liver transaminases monitored more frequently initially (at 
baseline, two weeks). Lipid and glucose levels should be monitored at baseline, three 
months, six months, and then yearly for protease inhibitor based regimens.. 
There is also need for periodic monitoring of plasma viral load and CD 4 cell counts 
while on therapy. These aspects will be described in detail below. 
Indications for changing therapy  
Major factors contributing to the durability of an initial regimen include antiviral potency 
of regimen, adherence, tolerability, convenience of the regimen, and baseline virologic or 
immunologic status. The four common indications for changing the antiretroviral 
regimen based on previous studies (24-26) include: 
• Toxicity  
• Treatment failure  
• Difficulty adhering to the regimen  
• Current antiretroviral regimen is suboptimal  
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In the Swiss HIV Cohort Study, Fellay et al described that 47% of patients on potent 
HAART had clinical adverse events and 27% had laboratory adverse events that were 
considered to be probably or definitely attributable to therapy.(27) In another US based 
ART naïve cohort of 3414 patients with a median follow-up of 211 days, Yuan et al 
documented that  628 patients (18.4%) reportedly discontinued the HAART regimen 
because of drug toxicity,  456 patients (13.4%) because of non-compliance, and 257 
(7.5% ) because of treatment failure.(26) 
Antiretroviral treatment failure: defined as a suboptimal response to therapy and is 
often associated with virologic failure, immunologic failure, and/or clinical progression. 
ART may need to be changed because of either treatment failure or toxicity. 
Treatment failure can be evaluated clinically, immunologically by measurement of the 
CD4 cell counts, and/or virologically by measuring viral loads. However, as the latter are 
not normally available in resource-limited settings like ours, it is recommended that 
programmes in such settings should primarily use clinical criteria and, where 
possible, CD4 cell counts, to define treatment failure.  
Factors increasing the likelihood of treatment failure based on previous studies have 
been: baseline patient factors such as earlier calendar year of starting therapy, higher 
pretreatment or baseline HIV RNA level (depending on the specific regimen used), lower 
pretreatment or nadir CD4 cell counts, prior AIDS diagnosis, co-morbidities (e.g. 
depression, active substance use), presence of drug resistant virus, prior treatment failure 
with development of drug resistance or cross resistance, non-adherence, drug toxicity and 
interactions.(25) 
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Incomplete virologic response is defined as repeated HIV RNA > 400 copies/mL after 24 
weeks or >50 copies/mL by 48 weeks in a treatment-naïve patient initiating therapy. 
Baseline HIV RNA may impact the time course of response and some patients will take 
longer than others to suppress HIV RNA levels. The timing, pattern, and/or slope of HIV 
RNA decrease may predict ultimate virologic response. For example, most patients with 
an adequate virologic response at 24 weeks had at least a 1 log10 copies/mL HIV RNA 
decrease at 1-4 weeks after starting therapy.(28) 
Blips — this term refers to intermittent periods of “detectable viremia” meaning viral 
loads >50 copies/mL. These are common and do not predict subsequent virologic failure. 
They do not require intervention with a new regimen unless the viral load is sustained at 
>50 copies/mL or perhaps >400 copies/mL.(29) 
Cross Resistance. ARV drug resistance is a consequence of mutations in viral proteins 
targeted by the ARV agents. Another contributing factor is the extensive genetic diversity 
of HIV-1 with high rates of viral replication and highly error prone reverse transcriptase 
enzyme. The estimated prevalence of mutations conferring resistance to NRTIs was 7.8 
%, and the prevalence was 3 % for NNRTIs and 0.7% for PIs according to Novak et al. 
(30) Cross-resistance among NRTIs is common but varies by drug. Most, if not all, 
NNRTI-associated resistance mutations confer resistance to the entire NNRTI class of 
drugs because the development of a single mutation, such as the K103N mutation, results 
in drug resistance. They also have a very low genetic barrier to development of 
resistance. 
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The following are the guidelines for changing an antiretroviral therapy regimen for 
virological failure: 
1. A detailed treatment history and past and current resistance test results to identify 
active agents (preferably 3 or more) to design a new regimen. In general, one active drug 
should not be added to a failing regimen because drug resistance is likely to develop 
quickly 
2. For the patient with virologic failure, one needs to perform resistance testing while the 
patient still is taking the drug regimen or within 4 weeks after regimen discontinuation . 
3. If three active agents cannot be identified, one needs to consider pharmacokinetic 
enhancement of protease inhibitors (with the exception of NFV) with Ritonavir and/or re-
using other prior antiretroviral agents. 
4. Adding a drug with a new mechanism of action (e.g. HIV entry inhibitor) to an 
optimized background antiretroviral regimen can add significant antiretroviral activity. 
(31) 
5. Other implications for routine resistance testing prior to initiation of antiretroviral 
therapy include chronically infected ART naïve individuals with spouse on antiretroviral 
therapy and in some cases of acute HIV infection. 
Immunologic Failure 
Immunologic failure can be defined as a drop of greater than 30 % in CD4 cell count 
from peak value or a decrease to below the baseline CD4 cell count on therapy.(32) Mean 
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increases in CD4 cell counts in treatment-naïve patients with initial antiretroviral 
regimens are approximately 150/µL over the first year. Immunologic failure may not 
warrant a change in therapy in the setting of suppressed viremia. There is no accepted 
definition of immunological failure which can be used if CD4 counts are not available. 
Clinical Progression  
Clinical Progression can be defined as the occurrence or recurrence of AIDS defining 
opportunistic infections (after at least 3 months on an ARV regimen, when the drugs have 
been given for a sufficient time). Differentiating clinical failure from immune 
reconstitution syndromes (which can be seen within the first several weeks after the 
institution of therapy if a sub clinical infection is present at baseline) can at times be 
extremely difficult. Changing therapy in setting of IRIS is not warranted. In one study 
conducted in Netherlands, Ferdinand et al noticed clinical progression (a new AIDS event 
or death) in 6.3% of patients during a median follow-up of 48 weeks.(25) 
Changing because of toxicity 
In the setting of a good therapeutic response, the development of a clearly definable 
toxicity permits single drug substitutions without compromising the overall regimen. In 
respect of other toxicities for which a specific causal agent cannot be identified, and/or of 
low-grade but intolerable side-effects that frequently compromise adherence, a complete 
regimen switch may be the ideal approach. If an interruption in therapy is indicated in 
order to deal with toxicity the entire regimen should be temporarily stopped so as to 
prevent the emergence of drug resistance. 
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Main class specific toxicities of ART are as listed: 
1.  NNRTI:  hypersensitivity. 
2.  NRTI:  mitochondrial toxicity. 
3.  PI:  metabolic disorders. 
4.  NtRTI:  proximal renal tubular dysfunction. 
Skin rash:  
NVP-associated rash develops in about 17% of patients, with serious, i.e. grade 3 or 4, 
rash requiring treatment discontinuation in about 6-8%. There does not appear to be 
cross-reactivity for rash between EFV and NVP.(33) Severe life threatening 
complications including SJS, TEN and DRESS syndrome have been described 
necessitating permanent discontinuation of the drug. Female gender, plasma HIV RNA 
load > 10,000 copies/mL, heterosexual transmission and abacavir treatment constitute 
risk factors associated with risk of rash.(34)  Use of a two week-lead -in dose escalation 
schedule while initiating NVP may reduce the incidence of rash. The role of steroids in 
NVP-associated rash is controversial.(35) 
Skin rash is also known to occur with abacavir and amprenavir. 
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Hepatotoxicity:  
Hepatotoxicity defined as at least 3-5 times elevation in liver enzymes (ALT/AST/GGT) 
with or without clinical hepatitis has been reported in patients receiving HAART. 
Hepatotoxicity can occur in the absence of rash or the hypersensitivity syndrome.  
The AIDS Clinical Trials Group (ACTG) has classified laboratory-defined hepatotoxicity 
based on changes in transaminase levels relative to the upper limits of normal (ULN):  
Grade 0    (less than 1.25 x ULN); 
Grade 1    (1.25-2.5 x ULN); 
 Grade 2   (2.5-5.0 x ULN);  
Grade 3    (5.0-10.0 x ULN); and  
Grade 4    (greater than 10.0 x ULN) 
Pathogenesis: 
First, an immune-mediated hypersensitivity reaction can develop within 18 weeks of 
starting NVP, with most cases occurring between day 10 and 30. Patients with this type 
of hepatotoxicity typically have concomitant constitutional symptoms that may include 
fever, skin reactions, malaise, and nausea. The second type typically occurs after 18 
weeks of NVP therapy and most likely represents an intrinsic toxic drug effect. 
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Among persons taking NVP, the incidence of an asymptomatic increase in hepatic 
transaminase levels is approximately 5-15%, with rates on the lower end of this range 
reported from studies that defined hepatotoxicity as a five-fold or greater increases in 
transaminase levels and rates on the higher end in studies that used a cut-off of a three-
fold or greater increase.(36,37) While most hepatic toxicities occur within the first 12 
weeks after the start of therapy, one-third of cases first occur after NVP therapy has been 
in progress for 12 weeks or more. The incidence of clinically symptomatic hepatitis 
among persons taking NVP is approximately 1%. 
.Identified risk factors for developing hepatotoxicity with NVP consist of female gender, 
chronic hepatitis C virus infection, chronic hepatitis B virus infection, a CD4 cell count 
greater than 250 cells/µL prior to starting NVP, and abnormal baseline transaminase 
levels.(36-38)  In patients affected by co-infection with hepatitis B or C or having an 
elevated CD4 cell count, there are data suggesting an immunological component to the 
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toxicity (IRIS) NVP should be permanently discontinued in patients with NVP-
associated hepatitis. 
 NVP should not generally be used as initial therapy in women with a CD4 cell count 
above 250/µL. Men with CD4 cell counts above 400/µL who are started on NVP may 
also be at increased risk for asymptomatic transaminase elevations, however most 
patients are not initiated on HAART at CD4 cell counts this high.  
Lactic acidosis/hepatic toxicity: 
Asymptomatic low-level hyperlactataemia has been reported in 21% of NRTI-treated 
patients but is not predictive of lactic acidosis; symptomatic hyperlactataemia is less 
common and severe lactic acidosis and hepatic steatosis develops in only a minority of 
patients. Lactic acidosis, the most severe degree of lactic acidemia, consists of venous 
lactate greater than 2 mmol/L (18 mg/dL) and an arterial pH less than 7.30. Several 
studies, when taken together, have shown detection of asymptomatic or mildly 
symptomatic lactic acidemia in 8-21% of patients receiving at least one NRTI.(39,40) 
Lactic acidemia with significant symptoms occurs less frequently, with an estimated 
incidence of 1.5-2.5% among persons taking NRTIs.  Although uncommon, lactic 
acidosis is associated with a high fatality rate (33-57%). Risk factors include the female 
gender, a high body mass index, prolonged NRTI use, and, possibly, pregnancy, acquired 
riboflavin and thiamine deficiency, and d4T use. 
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Pathogenesis: 
The proposed pathway of mitochondrial dysfunction is by inhibition of DNA polymerase 
gamma causing derangements in the oxidative phosphorylation and lactate homeostasis. 
In vitro, the order of strength of inhibiting polymerase gamma for the different NRTIs is: 
ddC >> ddI > d4T ZDV >>> TDF = 3TC = FTC = ABC.(41) 
The initial symptoms are variable; a clinical prodromal syndrome may include 
generalized fatigue and weakness, gastrointestinal symptoms (nausea, vomiting, diarrhea, 
abdominal pain, hepatomegaly, anorexia, and/or sudden unexplained weight loss), 
respiratory symptoms (tachypnea and dyspnea) or neurological symptoms (including 
motor weakness). Laboratory abnormalities can include hyperlactataemia, increased 
anion gap, and elevated aminotransferases, creatine phosphokinase, lactate 
dehydrogenase, lipase and amylase. Microvesicular steatosis is seen on histological 
examination of the liver. Cases have occurred as early as one month and as late as 20 
months after the commencement of therapy.  
ART should be discontinued in patients with these symptoms, because otherwise there 
may be progressive toxicity with severe lactic acidosis and respiratory failure. Symptoms 
associated with lactic acidosis may continue or worsen following the discontinuation of 
ART. Therapy is primarily supportive (fluid, bicarbonate administration and respiratory 
support), although in uncontrolled cases the administration of riboflavin and/or thiamine 
has been described as beneficial. After the resolution of symptoms, regimens that can be 
considered for restarting ART include a PI combined with an NNRTI and possibly either 
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ABC or TDF. Nucleoside analogues are effective in inhibiting HIV replication due to 
their high affinity for the viral enzyme reverse transcriptase (a viral DNA polymerase).  
Drug induced anemia: 
AZT therapy is probably the most common cause of anemia in HIV-infected patients. In 
one of the earliest clinical trials placebo controlled trials with AZT in HIV infection, 
Richmann et al (42) discovered statistically significant reductions in hemoglobin levels in 
24% of subjects receiving AZT (1,200 mg per day) following 6 weeks of therapy. Twenty 
one percent of AZT-treated subjects in the trial required red blood cell transfusions while 
receiving the drug. Neutropenia was noted in 16 % of the patients. Marrow erythroid 
hypoplasia, aplasia, and megaloblastic maturation have developed as a result of AZT 
therapy. Subsequent studies have demonstrated that anemia is less common in patients 
with relatively less advanced HIV disease and in those receiving reduced dosages of 
AZT.(42, 43)  More recent studies of combination antiretroviral therapy have confirmed 
the relatively low incidence of severe anemia at lower doses of AZT (600 mg daily 
doses).(44). 
Hematological toxicity is dose-related and is more common in patients with advanced 
HIV disease, low CD4 cell counts and in those receiving concomitant bone marrow 
suppressive medications, such as ganciclovir, pyrimethamine or hydroxyurea. Other 
known determinants include patients with low serum vitamin B12 levels, anemia, or low 
neutrophil counts and concurrent use of acetaminophen.(42) 
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Effective therapy for AZT-induced anemia is available in the form of recombinant human 
erythropoietin. A double-blind, placebo-controlled study demonstrated that recombinant 
human erythropoietin (100 units/kg 3 times weekly by intravenous bolus) reduced 
transfusion requirements of AZT-treated HIV-infected patients whose serum levels of 
endogenous erythropoietin were less than 500 IU per liter.(45) 
Peripheral neuropathy :  
The primary toxicity associated with stavudine based therapy is peripheral neuropathy, 
which is dependent on both the dose and the duration of treatment and is more common 
in patients with advanced HIV disease and those who are being treated with other 
neurotoxic drugs, including didanosine.. The symptoms usually resolve within 2-3 weeks 
after the discontinuation of d4T. Rare occurrences of ascending neuromuscular weakness, 
including respiratory failure and death, resembling Guillain-Barre syndrome, have been 
reported in patients receiving stavudine; most cases have had concomitant lactic acidosis 
or hyperlactataemia. This forms one important reason for peripheral neuropathy in HIV 
infected adult. The exact pathogenesis is not known however could involve drug induced 
mitochondrial toxicity. Risk factors for developing peripheral neuropathy during 
nucleoside analogue therapy include low CD4+ cell count (<100 cells/µL), a prior history 
of an AIDS defining illness or neoplasm, a history of peripheral neuropathy, use of other 
neurotoxic agents including high alcohol (ethanol) consumption and nutritional 
deficiencies such as low serum hydroxocobalamin levels.(46) 
 
 30
Other toxicities seen: 
Efavirenz: central nervous system effects and teratogenicity bone disorders. 
Protease inhibitors: insulin resistance/diabetes, hyperlipidaemia, lipodystrophy, 
hepatitis, increased bleeding episodes in haemophiliacs. 
Drug interactions causing inhibition of cytochrome p 450 system causing increased drug 
level can lead to toxicity especially with boosted protease inhibitor regimen. 
Adherence: 
Adherence to the regimen is essential for successful treatment and hence has been rightly 
phrased as the “Achilles heel” of antiretroviral therapy.(47) Optimal adherence is the 
compliance to ART that achieves a sustained plasma drug concentration that will inhibit 
viral replication. In the treatment of patients with HIV infection or the acquired 
immunodeficiency syndrome, it is essential to achieve more than 95 % adherence to 
HAART in order to suppress viral replication and avoid the emergence of resistance. 
However with the advent of boosted regimens and considering the longer half life of 
NNRTIs, cut off rates of 90 % can be acceptable. 
Adherence rate = (number of pills expected to be taken– number of pills missed x 100)  
     Number of pills expected to be taken   
The adherence rate varies not just between individuals, but also in the same individual 
over time,(48)  thus making adherence a variable rather than a stable characteristic of an 
individual. Most people will exhibit low adherence at some time during this extended 
therapy. Studies have indicated that at least 95% adherence to ART regimens is optimal, 
with 95% adherence, viral suppression to below detectable levels occurs in 80%. 
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However, a fall in adherence to 70% (i.e. 25% less than optimal) drastically decreases 
viral suppression to 33% (i.e. less than 50% achieved with optimal adherence).(49) Also, 
it has been demonstrated that a 10% higher level of adherence results in a 21% reduction 
in disease progression. 
Measuring adherence in clinical practice is however difficult. Self reporting and pill 
counts are the simplest ways of assessing adherence to therapy.(50) Indirect ways like 
checking the mean corpuscular volume for patients on AZT could be useful. Adherence is 
promoted by simplified, well tolerated regimens involving as few pills as possible 
administered no more than two times a day. 
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PATIENTS AND METHODS 
 
 
Study Setting: 
The study was conducted in Christian Medical College Hospital, Vellore, a 1800 
bedded academic medical center in south India. 
Eligible subjects were recruited from the ‘Infectious Diseases Clinic’ (ID Clinic) which is 
a dedicated outpatient service for PLHA. 
The ‘ID Clinic’ is manned by staff from the departments of General Medicine and 
Infectious Diseases, Dermatology and Venereology, Child Health, Obstetrics and 
Gynecology, Psychiatry, counselors, social workers and pharmacists.  
The clinic serves as a “one stop shop” to provide comprehensive, holistic care for 
PLHA. The services offered include:   
1. Voluntary confidential counseling and testing (VCCTC) services,  
2. Diagnosis, treatment and prevention of sexually transmitted infections, 
3. Diagnosis, treatment and prevention of opportunistic infections (OI), 
4. Nutritional counseling and interventions, 
5. Antiretroviral therapy (ARV pharmacy, dedicated pharmacist, adherence 
counseling and monitoring), 
6. PPTCT of HIV infection programmes, 
7. Psychosocial interventions.  
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The clinic functions once every week. The average attendance is around 100 patients per 
outpatient clinic. All patients have open access to the clinic and are encouraged to attend 
the General medicine OPD or the emergency services whenever ill.     
Emphasis is placed on continuous patient education, in which medical social workers, 
specialized in HIV medicine, play a major role. 
 
Study Design: 
 
A prospective cohort study 
The study design and methods were approved by the Research Committee (Institutional 
Review Board) of Christian Medical College, Vellore. 
 
Subjects:  
The study recruited HIV infected adults attending the Infectious Diseases Clinic. 
The subjects were residents of southern Indian states (Tamil Nadu, Andhra Pradesh, 
Kerala and Karnataka).       
The HIV status was confirmed by a dually reactive ELISA test. 
All subjects satisfied the medical eligibility for initiation of antiretroviral therapy  
(WHO stage III /IV or WHO stage I/II with CD4 counts less than 200 cells/µL)  
The subjects had to be ART naive (defined as having received less than 4 weeks of ART 
prior to enrolment) and had to be initiated on HAART after March 1, 2004. 
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Exclusion criteria:      
      1. Pregnancy        
      2. Lactation  
      3. Age less than 12 years 
 
Subject enrolment: 
 
ART-naïve HIV infected adults eligible for and initiated on HAART after March 1, 2004 
were included in the study. All patients satisfying the inclusion criteria were subjected to 
a standardized clinical interview at the time of enrolment.  Baseline anthropometric data 
including weight, height, body mass index (BMI) were recorded. A blood sample was 
drawn for baseline complete blood counts (CBC), biochemical tests (blood glucose, liver 
and renal function tests), CD4 counts and plasma viral load (if feasible).  
All these details were recorded in a standardized proforma (see Appendix). 
All subjects had a detailed symptom directed clinical evaluation to rule out any active 
opportunistic infections prior to initiation of HAART. 
Follow up clinical assessments were done every 3 months. Clinical evaluation included  
symptomatology and detailed physical examination. Cohort surveillance was mainly 
passive. Patients had open access to the study clinic and were encouraged to attend 
whenever ill. Each episode of illness was investigated and managed according to 
established protocols. 
The review of patients for the study ceased on May 31, 2006 
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Study outcomes: 
 
Primary outcome was the incidence of failure of the initial HAART regimen in the 
cohort. “Failure” was defined as any event which necessitated a change in or 
discontinuation of the initial HAART regimen. This included 
1. Death from any cause. 
2. Clinical failure: Clinical failure was defined as the diagnosis of a new AIDS- 
defining illness three months (to exclude IRIS) after the initiation of HAART. 
3. Immunological failure: Immunological failure was defined as a decline in CD4 
cell counts below baseline values or failure of CD4 cell counts to increase above 
baseline values six months after initiation of HAART. CD4 cell counts were 
determined by immunophenotyping (flow cytometry or GUAVA). 
4. Virological failure: Virological failure was defined as either lack of viral 
suppression to below lower limit of quantification after six months of initiation of 
HAART or rebound increase in the viral load above the limit of quantification 
during the study period after an initial suppression. Plasma HIV viral load was 
determined using ‘Real Time RT-PCR’ (reverse transcriptase- polymerase chain 
reaction). The lower limit of quantification using the above technique was HIV 
RNA less than 53copies/mL. 
5. Non-adherence to therapy: Non-adherence was defined as ingestion of less than 
90 % of the prescribed doses. Adherence was assessed by patient self reporting 
and confirmed by pill count. Patients who never returned for follow-up after 
initiation of HAART were also considered to be non-adherent. 
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6. Serious ADR: defined as drug toxicities necessitating a regimen change. These 
have been discussed in detail below. 
 
Secondary outcome was the incidence of severe adverse drug reactions (ADR). The 
main ADR necessitating regimen change includes NNRTI induced hypersensitivity 
reactions (severe rash and hepatitis) and NRTI induced complications like severe anemia, 
lactic acidosis and peripheral neuropathy. 
 
a) Severe Drug Rash:  
Occurrence of serious cutaneous manifestations like Stevens-Johnson Syndrome (SJS), 
Toxic Epidermal Necrolysis (TEN) or the syndrome of drug rash, eosinophilia and 
systemic symptoms (DRESS syndrome) in patients receiving HAART. 
b) Hepatitis: 
Hepatitis was defined as an elevation in serum transaminases (AST/ALT) to more than 
five times the upper limit of normal with or without symptoms after initiation of therapy. 
c) Severe anemia: 
Bone marrow suppression manifested by hemoglobin less than 8 g/dL, total leucocyte 
count less than 4000 cells/µL and platelet count less than 100,000/µL after initiation of 
therapy. 
d) Symptomatic hyperlactatemia:  
Patients on antiretroviral therapy with 
1. Symptoms (which include fatigue, malaise, weight loss, anorexia, nausea, vomiting, 
dyspnea) 
 37
 2. Metabolic acidosis (arterial pH less than 7.30 or bicarbonate less than 20 mmol/L) 
with increased anion gap (more than 20 mmol/L) 
3. Elevated venous lactate concentration (>2 mmol/L, sample collected in a standardized 
manner**) 
**The following are the standard America and the Adult AIDS Clinical Trials Group 
(AACTG) guidelines for specimen collection to determine venous lactate levels: 
a) Have subject sit, relaxed for 5 minutes prior to venipuncture 
b) Instruct subject to not clench the fist before or during the procedure and to relax 
the hand as much as possible 
c) If possible, do not use a tourniquet. If a tourniquet is necessary, then apply 
tourniquet lightly and draw lactate first before the other samples with the 
tourniquet still in place 
d) Collect the blood in a chilled gray-top (sodium fluoride-potassium oxalate) tube 
e) Place the specimen immediately on ice and send to the laboratory for immediate 
processing, preferably within 30 minutes of collection.  
 
4. Other causes of lactic acidosis like pancreatitis, dehydration, septicemia and acute 
hepatic failure need to be ruled out before confirming diagnosis of lactic acidosis. 
 
e) Symptomatic peripheral neuropathy:   
Peripheral neuropathy was ascertained based on signs and symptoms and could include 
sensory symptoms like tingling, numbness, loss of any sensory modality with or without 
motor deficits after initiation of ART. Symptomatic (intolerable sensory symptoms or 
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motor signs reported by the patient) peripheral neuropathy requires an interruption in 
treatment. 
 
Statistical analysis: 
 
Data entry was done using the Statistical Package for the Social Sciences (SPSS) 
 
 software package (version 11). Descriptive statistics were calculated using SPSS 
 
 software. Chi-square test was used for comparison of categorical variables. Odds ratio  
 
(OR) and confidence intervals (CI) were calculated and a ‘p’ value less than 0.05 was 
 
 considered statistically significant. All reported p values are two-sided. 
 
Univariate logistic regression models were constructed with “failure of HAART” as  
 
the dependent variable to determine the predictors of failure .  
 
Variables with p < 0.15 in the univariate model were entered in the multivariate model.  
 
Baseline parameters considered as possible predictors of the final outcome were age, sex,  
 
WHO clinical stage of illness, baseline CD4 cell counts, regimen used etc. 
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R E S U L T S 
Baseline characteristics: 
Between March 1, 2004 and May 31, 2006 (27 months), a total of 230 consecutive ART 
naive patients were enrolled into the study and followed up for a median period of 48 
weeks.  
The baseline characteristics of the patients are as listed below: 
The study population mainly comprised of males (74.8%). The median age of the study 
population was 37 years (IQR, 34-44, mean (+ S.D), 38.9 (+ 8.4) years). 
 
     Table 1:    Age category     
Age (in years) Number (%) 
 
21-30 
 
37       (16.1) 
 
31-40 
 
118       (51.3) 
 
41-50 
 
54      (23.5 ) 
 
51-60 
 
18       (7.8 ) 
 
61-70 
 
3       (1.3) 
 
Total 
 
230      (100) 
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The mode of acquisition of HIV infection was heterosexual transmission in the majority 
(98.7%). Two patients had transfusion transmitted HIV infection and one acquired 
infection through homosexual contact. 
Majority of the patients had advanced stages of HIV infection, belonging to either WHO 
clinical stage III or IV (70.4 %). The distribution was as follows: 
 
  Table 2: WHO clinical stage of illness   
      
 
WHO stage 
 
Number (%) 
 
WHO stage 1 
 
               8       (3.5)             
 
 
WHO stage 2 
 
 60       (26.5) 
 
WHO stage 3 
 
           104      (45.2) 
 
WHO stage 4 
 
58      (25.2 ) 
 
Total 
 
230       (100) 
 
 
The median hemoglobin prior to initiation of HAART was 11.75 g/dL (IQR, 10.25-13). 
The median serum creatinine prior to initiation of HAART was 0.9 mg/dL (IQR, 0.8 – 
1.1, mean (+ S.D), 0.94 (+ 0.18) mg/dL) 
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 Baseline CD4 cell counts: 
 
Median CD4 cell counts prior to initiation of HAART: 127.72 cells/µL 
Inter-quartile range: 57 – 189.75 cells/µL 
Mean CD4 cell counts prior to initiation of HAART: 112.5 (+ 81.06) cells/µL. 
 
Table 3: Distribution of individuals based on CD 4 counts  
 
 
CD 4 category 
 
Number (%) 
 
Missing 
 
 
              30 
 
< 50 
 
 
              42            (21) 
 
50 - 200 
 
            113         (56.5) 
 
> 200 
 
              45         (22.5) 
 
Total 
 
            200          (100) 
 
 The absolute lymphocyte count was less than 1200 cells/µL in 58.1% of the patients.  
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d4T based regimen was used in 76% of the patients. 
NVP was the NNRTI in 86% of the patients. 
 
 
 
 
 
 
 
 
d4T + 3TC + NVP, 
157, 68%
AZT + 3TC + NVP, 
41, 18%
d4T + 3TC + EFV, 
18, 8%
AZT + 3TC + EFV, 
14, 6%
Figure 1: HAART Regimen Used 
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Twenty six (11.3 %) of the 230 patients also received concomitant anti-tuberculous 
therapy. 
Concurrent trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis was being used in 
99.6 % of patients. One patient was allergic to the above and received dapsone for 
prophylaxis. 
 
Follow up: 
The median duration of follow up was 48 weeks (IQR, 16 - 52 weeks, mean (+S.D), 39 
(+/-24.2) weeks). 
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Failure of initial HAART regimen: 
 
During the median duration of follow up of 48 weeks, 91 patients (39.6%) of patients 
experienced failure of their initial HAART regimen and had to either discontinue or 
change their initial HAART regimen.  
 
Table 5: Causes of failure of initial HAART regimen  
 
 
 
            Event 
  
      Frequency (%) 
 
Incidence rate 
(per 100  
person-years)     
 
Drug toxicity 
 
     62    (68.1) 
 
35.9 
 
Non-adherence 
 
     19    (20.9) 
 
          11 
 
Clinical failure 
 
      7      (7.7 ) 
 
4.1 
 
Deaths  ** 
 
      3      (3.3) 
 
2.4 
 
Total 
 
    91     (100) 
 
 
 
 
The median time to regimen failure was 12 weeks.  
** Eight patients died during the follow-up (incidence rate of 4.6/100 person-years). 
Three of them were attributed to clinical failure, two were due to ADR and three were 
due to unrelated causes. 
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Figure 2: Kaplan – Meir survival analysis curve plotting the proportion of patients 
still continuing their initial regimen. 
 
Around 60.4% of the patients are on their initial HAART regimen at the end of the 
median follow up period of 48 weeks as shown in the survival analysis curve. There is a 
steep fall during the initial phase indicating that the chance of failure is maximum in the 
first few weeks on initiation of HAART. The reasons for early HAART failure included 
loss to follow up, occurrence of an early ADR like anemia and drug rash. 
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Reasons for failure of initial HAART regimen: 
 
1. Deaths:  
There were a total of 8 deaths (3.5%) in the study cohort. The incidence rate was 4.6/100 
person-years. Five of them were due to failure of HAART and three of them were due to 
unrelated causes. Two patients died of ADR- one patient each developed TEN and lactic 
acidosis. Three patients died due to disease progression while on HAART (clinical 
failure). 
2. Adverse Drug Reactions: 
Serious ADR occurred in 62 patients (27%) and was the commonest cause of failure of 
the initial HAART regimen in the study cohort  
The incidence rate for ADR was 35.9/100 person-years. 
The incidence and profile of individual drug toxicities is illustrated in detail in the 
subsequent sections. 
3. Non-adherence:  
Nineteen patients (8.3%) had to discontinue their regimen due to non-adherence. As 
mentioned before adherence rates were calculated using patient self report and pill count  
and patients with adherence rates persistently below 90 % were termed non-adherent. The 
patients who did not follow up after initiation of HAART have also been included in this 
analysis. 
The incidence rate for non-adherence was 11/100 person-years.  
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4. Clinical Failure: 
Seven patients (3%) developed newer AIDS-defining illnesses during the follow-up 
period, an incidence rate of 4.1/100 person years. The major illnesses were disseminated 
tuberculosis which occurred in all seven patients and cytomegalovirus infection in one 
patient. Four of these patients also had oropharyngeal candidiasis. Three patients 
eventually succumbed to these illnesses. 
 
Immune Reconstitution Inflammatory Syndromes: 
Overall, eleven patients (4.8%) developed IRIS. The incidence rate for IRIS was 6.4/100 
person-years. Ten patients developed IRIS with Mycobacterium tuberculosis. These 
immune reconstitution syndromes occurred within the first three months of initiation of 
HAART and these patients required a change from a NVP- based regimen to an EFV- 
based regimen to avoid potential drug interactions between NVP and Rifampicin. One 
patient developed immune restoration illness with Cryptococcus neoformans; however he 
continued the initial HAART regimen. 
 
Determinants of failure of initial HAART regimen: 
 
A univariate logistic regression analysis showed the following parameters to be 
predictors of failure of initial HAART regimen (see table):  
1. Advanced HIV infection (WHO clinical stage III, IV) [OR 1.59, 95% CI (1.38-1.88)]. 
2. BMI > 25 [OR 1.56, 95% CI (1.18-2.06)]. 
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3. Concurrent smoking [OR 2.16, 95% CI (1.52-3.06)]. 
4. AST levels > 40 U/L [OR 2.26, 95% CI (1.47-3.47)] 
5. ALT levels > 40 U/L [OR 4.07, 95% CI (2.36-6.99)] 
6. Duration of illness before initiation of HAART more than 3 months [OR 1.22, 95% CI 
(1.04-1.44)]. 
 
Age, sex, HIV transmission category, CD4 cell counts and individual regimens were not 
associated with the failure of initial HAART. 
 
When the parameters with P value < 0.15 were entered in the multivariate logistic 
regression analysis, advanced HIV infection, BMI more than 25, baseline elevated 
alanine aminotransferases (ALT) and concurrent smoking remained predictive for 
HAART failure. 
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Table 6: Predictors for failure of initial HAART regimen (univariate) 
Parameter 
 
 
Female sex 
 
Advanced HIV 
( WHO clinical 
stage III, IV ) 
 
BMI > 25 
 
Smoking 
 
Duration of illness 
>3 months 
 
 
CD4 < 200 /µL 
 
ALC < 1200 /µL 
 
 
Diabetes mellitus 
 
 
Creatinine  
clearance  < 50 
mL/min 
 
AST > 40 U/L 
 
ALT > 40 U/L 
 
TMP-SMX 
prophylaxis 
 
Concurrent ATT 
 
AZT- based 
regimen 
Odds ratio 
 
 
     1.11 
 
     1.59 
 
 
      
     1.56 
 
     2.16 
 
     1.22 
 
      
 
     1.02 
 
     1.21 
 
      
     0.62 
 
 
     1.10 
 
 
    
     2.26 
 
    4.07 
 
    1.01 
 
 
     1.18 
 
     1.59  
95% CI 
 
 
0.71-1.74 
 
1.38-1.88 
 
 
 
1.18-2.06 
 
1.52-3.06  
 
1.04-1.44 
 
 
 
0.88-1.19 
 
0.97-1.50 
 
   
0.22-1.74   
 
 
0.96-1.04   
 
 
 
1.47-3.47  
 
2.36-6.99 
 
0.99-1.02   
 
 
0.57-2.43 
 
0.91-2.72    
P value 
 
 
   0.636 
 
 <0.001 
 
 
  
<0.001 
 
<0.001 
 
  0.017 
 
 
 
  0.791 
 
  0.093 
 
   
  0.359 
 
 
  0.938 
 
 
  
   0.009 
 
 <0.001 
 
  0.393 
 
 
  0.663 
 
  0.100 
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Severe adverse drug reactions: 
 
 
Severe ADR was the commonest cause of discontinuation of initial HAART in our study 
population (62 patients, incidence rate of 35.9/100 person-years). 
 
 Table 7:  Incidence of ADR 
 
 
ADR 
 
Frequency 
(Cumulative 
incidence) 
 
Incidence rate ( per 
100 person-years) 
 
Symptomatic hyperlactatemia 
 
         20     (8.7%) 
 
           11.6 
 
Severe anemia 
 
         16     (7.0%) 
 
             9.3 
 
Peripheral neuropathy 
 
         12     (5.2%) 
 
             7.0 
 
 
Severe drug rash 
 
   
          9      (3.9%) 
 
 
             5.2 
 
 
Hepatitis 
 
 
          3     (1.3 %) 
 
 
             1.7 
 
 
Others (pancreatitis) 
 
 
          2     (0.9 %) 
 
 
 1.1   
 
Total 
 
       62      (27%) 
 
          35.9 
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The major determinants for occurrence of an ADR were: 
 
1. Advanced HIV infection [OR 1.39, 95% CI (1.21-1.61)] 
2. Smoking [OR 1.51, 95% CI (1.08-2.11)] 
3. BMI > 25 [OR 1.68, 95% CI (1.29-2.18)]  
4. AST > 40 U/L [OR 1.93, 95% CI (1.29-2.89)] 
5. ALT > 40 U/L [OR 2.48, 95% CI (1.6-3.49)] 
The other potential predictors for development of a severe adverse drug reaction are 
given in the table. 
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Table 8: Predictors for development of severe ADR 
Parameter 
 
Advanced HIV 
infection (WHO 
clinical stage III,IV)  
 
 
BMI > 25 
 
smoking 
 
Female sex 
 
CD4>200 cells/µL 
 
ALC<1200cells/µL 
 
 
AST > 40 U/L 
 
ALT > 40 U/L 
 
 
 TMP-SMX 
prophylaxis 
 
Concurrent ATT 
 
AZT-based regimen 
 
Creatinine  
Clearance  < 
70mL/min 
OR 
 
        
       1.39 
 
      
 
       1.68 
 
       1.51 
 
       1.19 
 
       1.13 
 
       0.97 
 
        
        1.93 
       
         2.48 
 
 
       1.01 
 
        
       0.48 
 
       1.58 
 
 
       0.99 
95% C. I 
 
 
  1.21-1.61 
 
 
   
  1.29-2.18 
 
  1.08-2.11 
 
  0.74-1.90 
 
  0.65-1.95 
 
  0.76-1.25 
 
   
  1.29-2.89 
 
  1.60-3.49 
 
 
  0.93-1.02 
 
  
 0.17-1.34 
 
 0.89-2.80 
 
 
 0.57-1.70 
P value 
 
       
     < 0.001 
    
 
     
      <0.001 
 
        0.02 
     
        0.487 
 
        0.677 
 
        0.811 
 
         
        0.002 
 
        0.001 
 
 
        0.538 
 
         
        0.14 
 
        0.119 
 
 
        0.964 
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Individual drug toxicities: 
 
 
 Severe Drug rash: 
 
The incidence of severe drug rash (SJS or TEN) was 5.2/100 person-years.  
Nine patients developed severe drug rash. NVP was the etiology in eight of them and one 
patient developed drug rash to AZT. The median time to discontinuation of therapy due 
to severe drug rash was 2 weeks [range 2-6 weeks].  
All patients received NVP in a once daily lead - in- dose for 2 weeks before escalation to 
twice daily dosage. 
The offending drug was discontinued in all these patients. One patient died of TEN 
syndrome due to NVP. 
 
Severe anemia: 
The incidence of drug induced anemia was 9.3/100 person-years.  
The median time to detection of anemia was 8 weeks [range 3-36 weeks].  
AZT was the offending drug in all the cases and discontinued. A d4T-based regimen was 
used instead. 
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Symptomatic hyperlactatemia: 
 
 
The incidence of symptomatic hyperlactatemia was 11.6/100 person-years.  
Hyperlactatemia occurred only in patients on d4T- based regimens. Median time to 
development of symptomatic hyperlactatemia was 42 weeks [range 24-67 weeks]. 
The mean HCO3 and anion gap levels for these patients were 15 (+ 5.3) mmol/L and  
22.5 (+ 6.4) mmol/L respectively. The mean venous lactate was 3.7 mmol/L. All these 
patients received a drug holiday and were later started on an AZT- based regimen which 
they tolerated well. One patient died due to severe lactic acidosis. 
 
Peripheral neuropathy: 
 
 
Incidence of peripheral neuropathy was 7/100 person-years. 
Median time to development of the same was 32 weeks [Range 20-56 weeks]. 
Peripheral neuropathy was more likely to develop with a d4T-based regimen. 
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                                        DISCUSSION 
 
 
This study reveals a very high rate of failure of the initial HAART regimen in a cohort 
of south Indian adults with advanced HIV infection. Majority (70.4%) of the patients had 
advanced clinical stages of HIV infection (WHO stage III/IV) or CD4 cell counts less 
than 200cells/µL (78.5%). The male preponderance implies that males have a better 
access to therapy rather than the epidemiological profile of HIV infection in our setup. A 
very high proportion of the patients were on d4T-based regimens (76.1%) and 86.1% had 
NVP as the NNRTI. At the end of the median follow-up period of 48 weeks, 39.6% of 
patients had either discontinued or changed their initial HAART regimen. These regimen 
failure rates are very high compared to references from published literature. In the study 
conducted at YRG CARE centre, Kumarasamy et al had described treatment modification 
rates of 20%, the main reasons being adverse events, cost and treatment failure.(5) In a 
US-based ART naïve cohort, Yuan et al had described treatment discontinuation rates of 
39.3% over a median follow up of 211 days.(26) 
 
The median time of follow up in our study was 48 weeks. It is important to realize that 
this time of 48 weeks is a relatively short time in view of the need for lifelong therapy. 
The incidence of regimen failure was higher in the first few weeks of initiation of 
HAART as shown in the Kaplan –Meier survival analysis curve earlier. The median time 
to regimen failure was 12 weeks. The reasons for HAART regimen failure during the 
initial phases of therapy were non-adherence/loss to follow-up and early ADR like 
anemia and severe drug rash. 
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Drug related toxicities are a frequent cause of modification of the initial HAART 
regimen. In our study, 27 % of the subjects developed severe ADR requiring either a 
change or discontinuation in the initial HAART regimen. The major ADR in our cohort 
were symptomatic hyperlactatemia (8.7%), severe anemia (7%) and peripheral 
neuropathy (5.2%). All these ADR are attributable to the thymidine analogue NRTI 
used in the backbone- either d4T or AZT. The mitochondrial toxicities of NRTIs 
appeared later during the course of therapy. The median duration to development of 
hyperlactatemia was 42 weeks and peripheral neuropathy was 32 weeks. An intriguing 
observation was that some patients who had discontinued the HAART regimen due to 
lactic acidosis actually reported symptoms suggestive of peripheral neuropathy during the 
earlier follow-up visits. The patients receiving NVP were at a higher risk of developing 
severe drug rash or hepatitis.  
 
 The major predictors for development of an ADR were advanced stages of HIV 
infection, obesity, elevated transaminases and concurrent smoking. Our findings are 
consistent with the recent publication by Kumarasamy et al in which ADR was a major 
cause of treatment modification in 64% of their study population. The best solution to 
increase the tolerability of HAART in view of the high incidence of thymidine analogue 
NRTI related ADR would be to start eligible PLHA on non-thymidine analogue NRTI 
like Tenofovir (TDF) which have favorable efficacy and safety profiles. 
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Another major observation was the low mortality (4.6/100 person-years) and disease 
progression rates (4.1/100 person-years). There were total of 8 deaths and 7 patients 
developed new AIDS-defining illnesses while on HAART. These findings confirm the 
effectiveness of generic HAART in substantially reducing the morbidity and mortality 
even among patients with advanced HIV infection. 
 
This study also reiterates the fact that by increasing the tolerability of HAART, one 
can achieve significant reductions in regimen failure rates.  
.  
The definition of “failure” of HAART regimen used in our study is a very practical one 
which incorporates regimen safety, tolerability and convenience, in addition to potency. 
The main causes of failure of a HAART regimen based on previous studies and adopted 
by the AIDS control trial group (ACTG) have been drug toxicities, clinical, virological or 
immunological failure and non-adherence to therapy. Serial monitoring of plasma viral 
loads and CD4 counts while on therapy might not be feasible in developing country with 
most centers having limited resources. Hence the decision to change a regimen is most 
often taken on the basis of serial clinical assessments, drug toxicities, development of 
newer AIDS-defining illnesses while on HAART etc. 
 
Eleven patients were diagnosed to have IRIS. These patients presented with opportunistic 
infections usually within the first three months of initiation of antiretroviral therapy. 
These do not represent failure of HAART. Majority of our patients had Mycobacterium 
tuberculosis presenting as immune reconstitution syndromes requiring a change from 
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NVP to an EFV based regimen to avoid drug interactions between RIF and NVP. The 
phenomenon of immune reconstitution is believed to occur due to initial rapid increases 
in CD4 counts due to redistribution of trapped memory T cells from the lymph nodes to 
peripheral blood, followed by a slower repopulation of newly produced naive T cells. 
 
Our cohort had relatively low non-adherence rates (11/100 person-years). The rate is 
lower when compared to previous studies which have documented rates as high as 
13.4%.(26) This is hugely attributable to the meticulous efforts by the support staff 
concentrating on aspects of patient education. Optimizing adherence is truly the 
cornerstone of a successful response to a HAART regimen.  
 
To summarize: 
1. The incidence of death and disease progression was low in this cohort, indicating 
effectiveness of HAART even in patients with advanced HIV infection. 
2.  The major cause of HAART failure was ADR, mainly to the thymidine analogue 
NRTI backbone components- d4T and AZT. Hence there is a need for selecting regimens 
with better safety profiles like Tenofovir based regimens to enhance the tolerability and 
reduce the incidence of HAART failure. 
3. By recruiting full term personnel emphasizing on continuous patient education and 
limiting substance abuse through detailed psychosocial evaluation one can reduce the 
incidence of non-adherence. 
4. Advanced HIV illness is associated with a higher risk of HAART failure; hence there 
is a case for initiation of HAART earlier in the course of illness, though concerns about 
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the tolerability might always discourage initiation of HAART in relatively asymptomatic 
patients. 
 
The major limitations in our study include:  
1. The median duration of follow-up of 48 weeks actually represents a very short 
time frame considering the chronicity of the illness and the need for lifelong 
treatment. 
2. According to existing guidelines, there should be periodic monitoring of CD4 cell 
counts and plasma viral loads during the course of therapy to ensure that the 
regimen offers maximum virological suppression. Only one patient in our study 
cohort could afford serial monitoring of CD4 counts and plasma viral loads. 
 
Clearly, a lot of improvement is still needed in the field of antiretroviral therapy. 
1. To reduce the incidence of treatment failure, ART should cause lesser toxicity and 
adherence should become much easier. 
2. Risk factors other than patient reported reasons might contribute to treatment 
discontinuation. There is a need for identifying these risk factors and simplifying 
treatment regimens for maximizing effectiveness of ART.  
3. Cost effective monitoring tools need to be devised in developing countries with 
limited resources. 
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  CONCLUSIONS 
 
1. Two hundred and thirty consecutive ART naïve HIV infected individuals initiated 
on HAART after March 1, 2004 were followed up for a median period of 48 
weeks. 
2. Failure of the initial HAART regimen occurred in 91 (39.6%) of these patients. 
3. HAART regimen failure was mainly due to ADR (68.1%), non-adherence 
(20.1%) and clinical failure (7.7%). The commonest ADR were symptomatic 
hyperlactatemia (8.7%), severe anemia (7%) and peripheral neuropathy (5.2%) 
which was either due to the d4T/AZT component of the HAART regimen. 
4. The main predictors for HAART regimen failure were advanced HIV infection, 
obesity, concurrent smoking, elevated transaminases and duration of illness 
before initiation of HAART more than 3 months. 
5. The incidence of mortality in our study cohort was low (4.6/100 person-years) 
6. The incidence of newer AIDS-defining illnesses signifying disease progression 
was also low (4.1/100 person-years) among this cohort with advanced HIV 
infection. 
7. The major determinants for occurrence of an ADR were advanced HIV infection, 
smoking, obesity and elevated transaminases. 
  
 
 
 
.                                            
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Objectives of the study: 
To determine the incidence and predictors of failure of the initial HAART regimen in a 
cohort of ART-naïve, HIV-infected south Indian adults 
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Methods: 
A cohort of ART-naïve HIV-infected south Indian adults who were initiated on HAART 
(as per WHO and NACO guidelines) after March 1, 2004 were prospectively followed 
up. “Failure” was defined as any event requiring either discontinuation or change in the 
initial HAART regimen. This included virological, immunological or clinical failure, 
serious ADR, non-adherence and death. A logistic regression analysis was performed to 
determine the factors associated with HAART failure. 
 
Results: 
Two hundred and thirty subjects were enrolled during the 27 months from March 1, 2004 
to May 31, 2006. The median age was 37 years (IQR, 34-44) and 74.8% of the subjects 
were males. Majority (70.4%) had advanced HIV infection (WHO clinical stage III/IV) 
and 79% had CD4 counts below 200 cells/µL. Stavudine-based regimen was used in 76% 
and 86% were on a NVP-based regimen. During the median follow-up of 48 weeks, 91 
(39.6%) patients experienced failure. The main reasons for failure were ADR (68.1%), 
non-adherence (20.9%) and clinical failure (7.7%). The most common ADR were 
attributable to the thymidine analogue NRTIs - d4T induced symptomatic 
hyperlactatemia (8.7%), peripheral neuropathy (5.2%), and AZT induced anemia (7%). 
The mortality (4.6/100 person-years) and disease progression rates (4.1/100 person-years) 
were low. Advanced HIV infection (OR 1.59), smoking (OR 2.16), BMI > 25 kg/sq.m 
(OR 1.56), deranged liver enzymes (ALT > 40U/L - OR 2.25, AST > 40U/L - OR 4.07) 
and longer duration of illness (OR 1.224) were associated with HAART failure. 
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Conclusion: 
HAART regimens used in this study, though effective in decreasing the rates of disease 
progression and death, were associated with high rates of ADR, particularly those 
attributable to thymidine analogue NRTI. Improving access, earlier initiation, careful 
screening at baseline and better tolerated drug regimens could potentially improve 
the outcome of these patients. 
 
 
 
 
 
  
 
 
 
 
Appendix I 
 
Proforma 
 
 1. Name                                                                      2. Age 
 
 3. Sex                                                                         4. Hospital No.     
 
  5. Address 
 
    Phone No. 
 
 6. smoker/nonsmoker 
 
 7. Occupation 
 
 8. Marital status: never married /currently married/separated/widowed 
 
 9. Education: Nil/primary/secondary/high school/college 
 
 
  
10. Date of diagnosis of HIV infection- 
 
      Test by which diagnosis made-   ELISA/Western Blot 
 
11. Opportunistic infections prior to HAART:  
                                                                                                                     
Date Opportunistic infection treatment 
   
   
   
   
 
                       
12. WHO clinical stage of infection (at initiation of HAART):  I /II /III /IV 
 
13. Diseases prior to initiation of ART: HTN/ DM/ Dyslipidemia/ others 
 
14. VDRL: Nonreactive/reactive                
15. HBsAg: positive/negative 
16. HCV ab :positive/negative       
17. Body weight:                          
    Height:                                           
18. BMI: 
 
  
19. Relevant physical findings: 
 
20. Investigations:   1 .Hb 
                               2. TC/DC                                      ALC                     
                               3. Platelets 
                               4. AC/PC 
                               5. Lipid profile 
                               6. LFT 
                               7. Serum creatinine 
                               8. CXR 
                               9. Urine protein                                  
 
21. CD4 counts (prior to HAART)                     
 
22.  HIV viral load 
 
23. HAART regimen:  
Regimen 1-Stavudine-30+lamivudine+nevirapine 
Regimen 2-stavudine-40+lamivudine+nevirapine 
Regimen 3-Zidovudine+lamivudine+nevirapine 
Regimen 4-Zidovudine+lamivudine+efavirenz 
Regimen 5-stavudine-30+lamivudine+efavirenz 
Regimen 6-stavudine-40+lamivudine+efavirenz 
  
 
Any others-to specify 
 
To specify whether any change in regimen at any time: 
 
24. Whether on: 1.ATT                  2.Bactrim                   3.MVT 
25. Drug toxicity: 
a. Dermatological: skin rash [ ],oral ulcers [ ] 
b.GI disturbances: nausea [ ],vomiting [ ],hepatitis [ ],pancreatitis [ ] 
c. Bone marrow toxicity: 
d. Metabolic:glucose intolerance [ ],dyslipidemia [ ],lipodystrophy [ ],lactic 
acidosis [ ] 
e. Neurological:peripheral neuropathy [ ],myopathy [ ] 
f. Renal stones [ ]                              
g.others: specify 
 
25. Whether any OI on HAART (IRIS)-specify also the mode of management 
 
 
 
 
 
 
 
 
 
 
26. Follow-up 
 
  
 
Date weight Adherence% toxicity CD4 PVL New events 
       
       
       
       
       
       
       
       
       
       
       
       
 
 
27. At end of study: 
        1. Weight 
                                2. Bodymass index 
                                3. Midarm circumference 
                                4. Hb 
                                5. Blood sugars 
                                6. Lipid profile 
                                7. ALC 
                                8. CD4 counts 
 
 
  
Consent form 
Title of study: Incidence and determinants of failure of initial HAART regimen in a 
cohort of ART naïve HIV infected South Indian adults. 
Institution: Department of Medicine and Infectious diseases. 
Purpose of study : A descriptive study to determine the incidence and determinants of 
treatment failure in a cohort of ART naïve HIV infected South Indian adults. 
 
Declaration by the patient 
 After initiation of ART, I agree to regularly follow up in the Infectious Disease OPD as 
per my doctors advice and also report any major events as explained by my doctors . I 
also understand that I have an open access to the study clinic and can report any time to 
either the department or emergency services if the need arises. 
I also understand that all my details and records obtained for the purpose of the study will 
need to be available to the doctor conducting the study , but will remain strictly 
confidential at all times. My identity will not be otherwise revealed. 
I have read the above information before signing the consent form. 
 
 
Place: 
 
Date:                                                                                           Name and signature 
 
 
 
                                                                             Signature of principal investigator 
 
 
 
  
Appendix II:   
 
GLOSSARY TO MASTER CHART 
 
 
1. Name 
 
2. Hospital number 
 
3. Age in years 
 
4. Sex (1 – female, 2 - male) 
 
5. Transmission: Mode of transmission (1-heterosexual, 2-homosexual, 3-IV drug    
abuse, 4-transfusion related) 
6. Stage: WHO stage of HIV illness (1-Stage 1, 2-Stage II, 3- Stage III, 4-Stage IV) 
7. Duration of illness prior to initiation of HAART in weeks. 
8. Co-morbidities: (0-none, 1-Diabetes mellitus, 2-Hepatitis B infection, 3-Hepatitis 
C infection, 4-syphilis, 5-others) 
9. Body weight (in kg) at time of initiation of HAART. 
10. Height in cms. 
11. CD 4 lymphocyte cell counts per cubic mm. 
12.  ALC: Absolute lymphocyte counts. 
13. Hemoglobin in g/dL. 
14. Serum creatinine in mg/dL.. 
15. AST:aspartate aminotransferase (1–normal < 40 U/L, 2–elevated >40 U/L) 
16. ALT: alanine aminotransferase (1–normal < 40 U/L, 2–elevated >40U/L) 
 
 
17. ART regimen used: (1-d4T + 3TC + NVP 
  
                                         2-AZT + 3TC + NVP  
                                         3-d4T + 3TC + EFV  
                                         4- AZT + 3TC + EFV ) 
18. Concurrrent use of TMP-SMX prophylaxis: (1-yes, 2-no) 
19. Concurrent antituberculous therapy (1-yes, 2-no) 
20. End point: treatment failure (1 –yes, 2-no) 
21. Reason for treatment failure/regimen discontinuation: (0- still on HAART 
                                                                                                1- drug toxicity 
                                                                                                2- clinical failure 
                                                                                                3- non-adherence 
                                                                                                4- death 
                                                                                                5- others ) 
22. Drug toxicity: (0- none, 
                               1- Drug rash, 
                               2- Hepatitis 
                               3- Anemia 
                               4- Hyperlactatemia 
                               5- Peripheral neuropathy 
                               6- Others 
23. Smoking: (1-yes, 2-no) 
24. Death:  (1 –alive, 2 – death) 
25. Total follow-up in weeks. 
 
 
  
Appendix III 
 
 
Revised WHO Clinical Staging of HIV/AIDS for Adults and 
Adolescents 
 
 
Primary HIV infection 
 
Asymptomatic  
Acute retroviral syndrome  
 
Clinical stage 1 
 
Asymptomatic  
Persistent generalized lymphadenopathy  
 
Clinical stage 2 
 
Moderate and unexplained weight loss (<10% of presumed or measured body weight)  
Recurrent respiratory tract infections (such as sinusitis, bronchitis, otitis media, 
pharyngitis)  
Herpes zoster  
Recurrent oral ulcerations  
Papular pruritic eruptions  
Angular cheilitis  
Seborrhoeic dermatitis  
Fungal finger nail infections  
 
Clinical stage 3 
 
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or 
simple investigations 
Unexplained chronic diarrhoea for longer than one month  
Unexplained persistent fever (intermittent or constant for longer than one month)  
Severe weight loss (>10% of presumed or measured body weight)  
Oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis (TB) diagnosed in last two years  
Severe presumed bacterial infections (e.g. pneumonia, empyema, meningitis, 
bacteraemia, pyomyositis, bone or joint infection)  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis  
 
Conditions where confirmatory diagnostic testing is necessary 
Unexplained anaemia (< 80 g/l), and or neutropenia (<500/µl) and or thrombocytopenia 
(<50 000/ µl) for more than one month  
  
 
 
Clinical stage 4 
 
Conditions where a presumptive diagnosis can be made on the basis of clinical signs or 
simple investigations 
HIV wasting syndrome  
Pneumocystis pneumonia  
Recurrent severe or radiological bacterial pneumonia  
Chronic herpes simplex infection (orolabial, genital or anorectal of more than one 
month’s duration)  
Oesophageal candidiasis  
Extrapulmonary Tuberculosis  
Kaposi’s sarcoma  
Central nervous system toxoplasmosis  
HIV encephalopathy  
 
Conditions where confirmatory diagnostic testing is necessary 
Extrapulmonary cryptococcosis including meningitis  
Disseminated non-tuberculous mycobacteria infection  
Progressive multifocal leukoencephalopathy  
Candida of trachea, bronchi or lungs  
Cryptosporidiosis  
Isosporiasis  
Visceral herpes simplex infection  
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or 
lymph nodes)  
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis)  
Recurrent non-typhoidal salmonella septicaemia  
Lymphoma (cerebral or B cell non-Hodgkin)  
Invasive cervical carcinoma  
Visceral leishmaniasis 
 
 
 
NAME H.no. age sex transmission stg duration comorbid weight height cd4 ALC hb crt AST ALT regimen bactrim
abdul kareem     254502c 44 2 1 4 156 0 49 166 97 1316 11 1 2 2 1 1
abdul suban      359424c 45 2 1 3 36 0 64 162 124 1700 13 1 2 2 1 1
adinarayana      033765c 40 2 1 3 140 0 44 168 223 2800 12 1 1 1 1 1
abooty           474084c 50 2 1 4 676 0 60 175 112 1456 10 1 1 2 4 1
ahmed jameel     138827c 38 2 1 4 148 0 50 171 13 832 9.4 0.9 2 1 1 1
alamelu          536611c 26 1 1 3 4 0 45 158 . 900 9.4 1 . . 1 1
amar             347336c 33 2 1 3 16 0 43 160 148 390 9.8 0.9 1 1 1 1
andiappan        535676c 46 2 1 3 4 0 55 169 74 462 12 1 1 1 1 1
annamalai        680996c 27 2 1 2 16 0 46 163 159 1224 15 0.8 1 1 1 1
anthony.x        424625c 49 2 1 2 12 0 56 168 162 978 12 1 1 1 1 1
annadurai        475449c 46 2 1 3 126 0 59 166 112 2340 16 2 1 2 1 1
arputha raj      841617b 41 2 1 3 156 0 54 162 43 925 8.3 1 1 1 1 1
arockiadoss      658904c 57 2 1 3 8 0 47 163 82 1182 10 0.7 2 2 1 1
arul.a           411892c 34 2 1 3 76 0 50 170 107 1463 11 1 1 1 2 1
aruna            488816c 30 1 1 2 4 0 45 168 272 2400 12 0.7 1 1 1 1
ashokan          573090c 43 2 1 3 16 0 44 169 69 968 11 0.6 2 2 1 1
babu.k           558566c 36 2 1 1 48 0 58 173 185 2400 14 1 1 1 1 1
babu.m           544829c 40 2 1 1 32 0 56 165 210 1794 12 0.9 1 1 2 1
balaji.b         159036c 40 2 1 4 104 0 59 161 18 980 10 0.8 1 1 3 1
balasubramaniam.r527509c 54 2 1 4 24 0 66 164 20 636 11 1 2 2 3 1
chandrayudu      423815c 33 2 1 3 48 0 60 174 64 . 7.5 1 2 1 1 1
baskaran.d       645584b 41 2 1 3 32 0 43 160 . 2870 13 1 1 1 1 1
baskaran.g       564232c 45 2 1 2 48 0 70 173 68 1196 12 0.9 1 1 1 1
baskar.v         719665c 40 2 1 3 12 2 73 171 302 1352 17 1 2 2 4 1
bhanumathi       610885c 45 1 1 3 24 0 45 151 25 1632 8.6 0.8 2 1 2 1
bhujamma         491258c 50 1 1 1 8 0 58 155 303 3000 11 1 1 1 1 1
brinda.s         709012c 46 1 1 2 4 1 48 151 . 1836 12 0.7 2 2 4 1
caroline mary    627091c 37 1 1 3 56 0 46 150 219 1829 9.9 0.8 1 1 3 1
chabungam anand  696833c 35 2 1 3 810 3 61 164 205 1406 16 0.9 2 2 1 1
chakrapani reddy 072199c 27 2 1 3 780 0 46 166 233 1750 12 0.9 1 1 2 1
challa lalitha   665245c 31 1 1 2 2 0 43 154 191 2160 9.9 0.7 2 2 1 1
chandran.r       439747c 35 2 1 2 2 0 51 166 126 740 12 0.8 1 1 1 1
chandradass.m.k  391517c 30 2 1 4 48 0 56 164 149 1155 13 1 1 1 1 1
chandramohan.c   518574c 50 2 1 3 16 0 42 167 . 1209 11 0.9 1 1 3 1
chandrasekhar.r  223757c 34 2 1 3 104 0 59 165 173 3150 12 1 1 1 1 1
chandrayudu.b    423815c 34 2 1 2 48 0 62 169 64 1242 12 1 1 1 1 1
chella venkataram665241c 37 2 1 2 4 0 65 172 50 1080 11 0.8 1 1 2 1
deva             861879b 52 2 1 2 260 0 69 175 327 1277 14 1 2 2 2 1
devaki           721009c 40 1 1 3 24 0 51 154 75 777 11 0.9 1 1 4 1
dhanalakshmi     316605c 27 1 1 3 66 0 55 148 272 1320 14 0.8 2 2 1 1
dhananjayan      505930c 40 2 1 2 4 0 55 168 202 1750 12 0.9 1 1 1 1
dharmalingam.r   646995c 36 2 1 2 8 2 70 174 100 672 12 0.7 2 2 3 1
duraimurugan     347422c 40 2 1 3 48 0 59 164 237 1296 14 1 1 1 1 1
elumalai         677811c 36 2 1 2 4 0 50 160 84 1290 14 0.9 1 1 1 1
emmanuel         432912c 35 2 1 4 36 0 56 154 24 740 11 0.8 2 2 1 1
eshwara prasad   514141c 32 2 1 3 104 0 60 168 200 1224 12 1 1 1 1 1
florence prabhaka310654c 34 1 1 2 104 2 46 150 133 976 10 0.9 1 1 1 1
ganapathy        179890c 39 2 1 2 52 0 83 170 237 3080 15 1 . . 1 1
ganesan.r        043172c 39 2 1 3 208 0 51 160 69 384 11 1 1 1 2 1
ganesh kumar     600287b 29 2 1 2 156 0 60 172 122 1144 17 1 1 1 1 1
gourishankar     191007c 30 2 1 4 104 0 49 158 . 1980 12 0.9 1 1 1 1
govindan.s.d     580861b 46 2 1 4 208 1 64 160 45 1188 13 0.9 2 2 1 1
govindaraj       650718c 34 2 1 2 8 0 60 173 141 1924 13 0.8 . . 1 1
govindaswamy     294987b 45 2 1 3 104 0 58 166 50 855 13 0.9 1 1 3 1
gunasekhran.g    545887c 38 2 1 3 24 0 65 160 50 868 13 0.9 1 2 1 1
haneefa t        434337c 40 2 1 3 12 0 69 171 128 720 7.8 1 1 1 3 1
hanumantha rao   633144c 55 2 1 3 24 0 64 172 118 1150 13 1 1 2 2 1
hari.v           563056c 34 2 1 3 8 4 67 168 186 1260 14 1 . . 2 1
janaki r         714471c 46 1 1 3 4 0 46 154 30 1700 12 0.8 1 1 1 1
jayakrishna.g    400385c 47 2 1 3 . 1 71 170 209 1800 8.2 1 1 1 1 1
jayapal.r        805187b 44 2 1 2 208 0 75 168 157 2000 15 1 1 2 1 1
jayshree.s       461906c 25 1 1 1 8 0 . . 229 1980 8.6 0.7 1 1 1 1
jeyachandran     600944c 56 2 1 4 104 0 35 169 . 316 9.8 0.9 1 2 1 1
jeyanthi         333356b 34 1 1 2 4 0 64 158 204 1400 14 0.8 1 1 2 1
johnson.o        737643c 39 2 1 4 8 0 40 158 10 852 11 1 2 2 1 1
juli.j           341422c 28 1 1 4 52 0 41 152 20 390 8.1 0.8 1 2 1 1
kala.m           161412b 40 1 1 4 520 4 56 150 111 1106 10 0.8 1 1 1 1
kanchana         743845c 31 1 1 3 2 0 38 148 17 1048 11 0.7 1 1 1 1
kaliappan.a      369114c 40 2 1 3 36 0 65 168 50 1080 13 0.8 1 2 1 1
kannan           426184c 32 2 1 3 16 0 66 170 222 . . . 1 1 1 1
karthikeyan      457963c 31 2 1 3 52 0 77 170 51 380 11 1 2 1 2 1
karupannan       453785c 54 2 1 4 16 1 56 171 59 1311 9.9 0.8 2 2 3 1
karunakaran      023646c 42 2 1 2 52 1 65 173 184 2136 12 1 1 1 1 1
kavitha.g        178308c 30 1 1 1 156 0 56 158 294 1304 12 0.8 1 1 2 1
konda reddy      609645c 47 2 1 3 8 0 55 172 102 860 9.2 1 2 1 4 1
koteeswari       591551c 29 1 1 3 16 0 54 156 . 1224 13 0.8 . . 1 1
kousalya         268093c 56 1 1 4 84 0 56 158 90 1150 11 1 2 2 1 1
kumar.k          801815c 30 2 1 3 104 0 54 162 . 1100 12 0.7 2 2 4 1
kumaresan.s      369640c 35 2 1 3 98 0 45 168 . 860 12 1 2 2 1 1
kuttilakshmi.v   591683c 38 1 1 2 84 0 53 157 121 1056 11 0.7 . . 1 1
lakshmi          322007b 34 1 1 4 208 0 40 153 . 868 8.6 0.9 2 2 1 1
lakshmi devi.p   646196c 28 1 1 3 4 0 38 148 201 1210 12 0.7 1 1 2 1
latha.d          928775b 35 1 1 3 208 0 47 149 102 555 . 0.7 1 1 1 1
madhesh.p        508789c 44 2 1 2 24 0 70 172 180 3000 15 0.9 1 1 2 1
madhubala.m      572866c 28 1 1 3 4 0 50 157 77 760 9.3 0.7 2 1 4 1
madhusudhan.y    964636b 29 2 1 3 452 0 45 161 32 1008 16 1 1 1 1 1
mageshwari.m     341317c 44 1 1 1 48 0 60 160 279 2310 13 1 1 1 1 1
maiyarasan       484716c 30 2 1 3 8 0 66 168 57 924 13 0.9 1 1 1 1
mahendran        063994c 36 2 1 4 208 0 51 169 . 824 8.4 1 1 1 1 1
malliga.m        728067c 34 1 1 3 156 0 55 156 207 3000 14 0.8 2 2 2 1
manogaran        255399c 44 2 1 3 24 0 48 175 110 980 14 0.8 1 1 1 1
mani k           255248c 34 2 1 2 104 0 66 171 101 1043 14 0.8 1 1 1 1
manita           424999c 36 1 1 2 52 0 56 152 205 1258 11 0.7 1 1 1 1
mohan r          591480c 40 2 1 3 8 0 62 172 195 1530 13 1 1 1 2 1
manu idiculla    649507c 35 2 1 4 8 0 54 167 53 600 14 0.9 1 1 2 1
mary suseela devi672441c 51 1 1 2 4 0 55 158 147 660 13 0.7 1 1 2 1
masilamani.s     725460c 38 2 1 2 52 0 60 171 . 1140 13 0.8 1 1 2 1
mohan babu       418920c 36 2 1 2 8 0 58 159 57 795 12 1 1 1 1 1
mohan rao        351749c 34 2 1 2 112 0 63 168 236 1280 15 1 1 1 2 1
munuswamy n      599627c 35 2 1 4 16 0 53 174 40 918 12 0.8 1 1 1 1
murali s         671659c 27 2 1 3 8 0 52 157 64 2094 12 1 1 1 1 1
murali mohan redd246549 32 2 1 3 98 0 56 166 146 2700 14 0.9 2 1 1 1
murugan.p        584365b 40 2 1 2 104 0 78 173 166 1600 15 1 1 1 1 1
murugan v        819687b 46 2 1 3 312 0 70 174 205 3712 12 1 2 1 1 1
murugesan v      625084c 35 2 1 2 4 0 60 169 42 935 13 0.8 1 1 1 1
muthu n          434876c 34 2 1 4 24 0 52 174 . 480 11 0.8 1 1 1 1
muthusamy        477615c 56 2 1 2 46 0 63 155 159 987 11 1 1 1 1 1
mylsamy          311378c 39 2 1 2 112 1 47 163 66 472 8.8 0.8 1 1 2 1
nagarathnamma    923657b 35 1 1 1 104 0 35 155 251 2576 12 0.8 1 1 1 1
nagendra prasd   447603c 30 2 1 3 54 0 52 169 111 1168 15 0.8 1 1 1 1
nageshwaran      701882a 44 2 1 4 24 1 61 172 . 1100 13 1 2 1 4 1
nallusami        585420b 38 2 1 3 424 0 58 166 59 1161 12 0.9 2 2 3 1
narasimhul naidu 357753c 35 2 1 3 104 0 50 160 173 1700 12 1 1 1 1 1
narasimha reddy m288067c 28 2 1 4 156 0 64 169 63 1142 13 1 2 2 1 1
narasimha reddy k488817c 36 2 1 3 8 0 64 163 50 870 11 1 1 1 1 1
natarajan        616678c 60 2 1 3 104 0 60 167 211 2376 13 0.9 1 1 2 1
natrayaswamy     378221c 46 2 1 4 56 0 44 152 43 1056 12 0.9 1 1 1 1
nookaraju d      638105c 50 2 1 3 16 0 53 161 118 1078 13 0.9 1 1 2 1
pachaiyappan m   177370b 50 2 1 3 28 0 58 171 50 896 9.2 1 2 2 1 1
padma            443633c 32 1 1 2 96 0 45 151 28 204 9 0.7 2 1 1 1
padm.j           955826b 34 1 1 4 208 0 38 145 241 3034 9.7 1 1 1 1 1
padmanathan s    185377c 48 2 1 4 260 0 67 165 48 720 14 1 2 2 1 1
palani m         702111b 31 2 1 4 156 0 42 154 . 549 12 0.9 . . 1 1
palani r         059814c 50 2 1 4 208 0 70 172 16 388 8.1 1 2 1 1 1
palaniammal      487453c 52 1 1 3 20 0 50 154 73 1157 9.8 0.9 1 1 1 1
palaniappan      540732c 70 2 1 3 4 0 52 174 50 1300 10 1 1 1 1 1
paneer selvam    461305c 50 2 1 4 4 0 69 174 130 2108 14 0.9 1 1 4 1
pandiyarjan p    301655c 40 2 1 3 32 0 66 156 171 1911 13 1 1 1 1 1
pandurangan d    385372c 38 2 1 4 52 0 40 163 273 1500 10 1 1 1 1 1
parthasarthy38   512137c 38 2 1 3 16 0 57 167 166 1108 12 0.8 1 1 2 1
pasala balasubbia888167b 34 2 1 4 260 0 57 163 . 312 8.1 1 1 1 1 1
patricia         184228c 43 1 1 4 104 0 35 153 61 432 7.9 0.9 1 1 1 1
pedda subba reddy262333c 58 2 1 3 26 0 59 164 117 1404 11 1 2 2 1 1
periyaswamy s    708349c 70 2 1 3 4 0 62 168 272 1425 13 1 1 1 4 1
pramila 512288c 58 1 1 3 58 0 70 159 120 1098 12 1 1 1 4 1
prathap reddy    566354c 43 2 1 1 27 0 41 167 69 689 8.2 0.8 1 1 4 1
radha kumari     521374c 40 1 1 4 8 1 53 152 50 380 9.1 0.7 1 1 1 1
raghavendra      913764b 35 2 1 3 56 0 44 173 113 762 13 1 2 2 1 1
raghu.a          093135c 29 2 1 2 208 0 57 180 77 900 11 0.9 1 1 2 1
raja m           464301c 40 2 1 4 48 0 62 165 . 2528 13 1 1 1 1 1
raja r           582282c 40 2 1 3 20 0 47 169 129 1126 10 1 1 1 1 1
rajambal.v       236358c 61 2 1 2 12 1 50 152 166 2700 11 0.6 1 1 1 1
rajendran        523595c 43 2 1 4 8 0 65 178 102 1150 17 1 1 1 1 1
raju             365079c 40 2 1 4 46 0 51 167 . 1120 9.6 0.8 2 2 1 1
ramachandran d   731875c 45 2 1 3 12 0 48 157 162 935 13 1 . . 1 1
ramamurthy       399251c 35 2 1 4 16 1 54 159 . 1140 14 0.8 2 2 1 1
rajamma          359673c 36 1 1 4 24 0 60 158 95 1105 12 0.8 1 1 1 1
ramanamma        422604c 24 1 1 3 104 0 45 152 57 750 8.1 . 2 2 1 1
ramanjulu        676019c 35 2 1 3 4 0 48 162 223 850 8.8 . 1 1 2 1
ramesh babu      523691c 32 2 1 3 4 0 40 157 260 1459 11 0.8 1 2 1 1
ranjith kumar    475454c 47 2 1 4 32 0 45 150 . 2467 9.3 0.7 2 2 2 1
ravichandran r   723306c 34 2 1 4 8 0 77 180 10 589 13 1 1 2 2 1
ravikumar        320286b 35 2 1 3 16 0 59 167 . 990 11 1 2 2 1 1
reddanna         725445c 50 2 1 3 8 0 44 153 48 920 9.9 1 2 1 1 1
reddappagiri srin360626c 34 2 1 3 82 0 52 163 149 1110 12 0.8 1 1 1 1
reddyiah         509894c 33 2 1 2 12 0 57 172 264 1690 15 0.9 1 1 1 1
renuka.n         490752c 28 1 1 2 29 0 55 155 135 2421 11 0.6 1 1 2 1
sampath r        401667c 28 2 1 4 28 0 35 157 30 700 12 1 1 1 3 1
sankari m        691341c 36 1 1 3 12 0 61 159 32 1110 9.9 0.6 2 1 1 1
santosh          592656c 38 2 1 4 12 0 55 170 . 1090 11 1 1 1 2 1
saravanan k      931243b 40 2 1 3 208 0 58 172 53 1123 12 1 1 1 1 1
saravanan s      302819c 30 2 1 2 64 0 51 169 202 1476 13 0.9 1 1 1 1
saravanan        019805c 31 2 1 2 212 0 55 170 278 1188 10 0.9 1 1 1 1
sashikumar d     557319c 28 2 1 3 208 0 84 174 311 1720 16 1 1 2 2 1
satish kumar     494491c 31 2 1 2 52 0 59 168 157 324 8.8 0.8 1 1 4 1
satya teertha    294967c 44 2 2 2 24 0 56 164 233 3008 . 0.9 1 1 1 1
savithri         563289c 37 1 1 3 24 0 46 154 47 898 8.9 0.8 1 1 2 1
sekhar d r       192874c 34 2 1 3 104 0 65 170 268 1342 9 1 1 1 1 1
selvaraj c       654906c 45 2 1 4 18 0 55 169 63 320 7.9 1 2 2 3 1
selvaraj m       590584c 34 2 1 3 54 0 73 171 132 990 14 0.9 2 2 2 1
selvi s          210923b 42 1 1 4 520 0 38 149 . 1100 10 0.7 1 1 1 1
seranjivi t      503684c 34 1 1 3 18 0 60 164 212 1548 12 0.7 1 2 1 1
sethuraman       674029c 57 2 1 3 10 0 50 152 92 1780 9.1 1 1 1 1 1
shankar r        256196b 36 2 1 4 208 0 60 168 . 480 11 1 2 1 1 1
shujath          746233c 36 2 1 4 4 0 65 173 136 1140 12 1 1 1 2 1
sibin mathew     977324b 30 2 1 3 208 0 54 162 . 1183 9.3 0.8 1 1 1 1
silambarasan     195439c 25 2 1 4 156 0 43 159 33 989 9.7 0.8 1 1 1 1
siromani         262140c 42 1 1 3 104 0 60 163 62 780 14 0.7 1 1 1 2
sivakumar g      458772c 34 2 1 3 24 0 76 174 62 . . . . . 1 1
sivakumar s      183663c 40 2 1 3 52 0 58 161 83 1108 11 1 2 2 1 1
sivaprasad r     564667c 36 2 1 4 4 0 51 160 92 1188 11 1 . . 1 1
siva reddy       561188c 43 2 1 2 48 0 71 174 153 2160 14 0.8 1 1 1 1
sivasami s       654477c 37 2 1 4 6 2 45 164 30 680 13 0.9 2 2 1 1
soundarrajan k   031025c 36 2 1 4 156 0 40 164 . 1138 9.8 1 2 2 2 1
soundarrajan m   195236c 44 2 4 2 104 1 46 157 205 1640 8.9 0.8 1 1 1 1
sreenivasan cr   562093c 38 2 1 2 24 1 76 168 134 1148 11 1 2 1 1 1
sriniva rao      615559c 38 2 1 2 4 0 75 178 198 1060 12 1 1 1 2 1
sreenivasu       591773c 32 2 1 2 4 0 52 160 182 1090 13 0.9 1 1 1 1
stevenson        497967c 51 2 1 2 8 0 60 168 52 1332 11 0.8 1 1 3 1
subramani k      434693b 47 2 1 2 106 4 55 164 182 2548 14 1 1 1 1 1
subramanyam m    467205b 50 2 1 2 156 0 47 167 195 1582 14 0.9 1 1 1 1
subramaniam n    542869c 42 2 1 4 8 0 54 165 65 1280 11 0.9 1 1 1 1
subramaniam ns   567746c 46 2 1 4 52 0 52 170 19 679 14 1 2 2 1 1
sujatha h        736678b 33 1 1 2 156 0 53 152 85 860 13 0.8 1 1 1 1
sujatha k        367149b 27 1 1 2 16 0 42 144 . 3220 12 0.8 1 1 1 1
sumathi k        937700b 29 1 1 3 104 0 41 156 . 1890 11 0.9 1 1 1 1
venkateswar      687708C 30 2 1 2 16 0 45 151 230 1212 12 0.8 1 1 1 1
sundara mahalinga440385c 30 2 1 4 8 1 59 163 130 600 11 1 1 1 3 1
sundara vadivel  470725c 40 2 1 2 48 0 60 168 168 866 14 0.7 1 1 1 1
sunil kumar m    627481c 30 2 1 2 8 0 85 170 179 2520 14 1 1 1 1 1
surabhi sridha   497237c 33 1 1 3 52 0 81 172 101 1530 14 1 1 1 2 1
surendranath     367446c 30 2 1 3 104 0 51 160 81 224 11 1 1 2 1 1
suresh g         446896c 34 2 1 3 4 0 44 162 33 600 7.9 0.7 2 1 3 1
suresh gupta     201426b 35 2 1 3 314 0 53 163 134 800 15 0.9 1 1 2 1
suresh p         961202b 35 2 1 3 104 0 53 166 . 1061 10 0.8 1 1 3 1
surya            434041b 37 2 1 2 52 0 51 172 326 2816 13 1 1 1 1 1
selvi t          389318c 38 1 1 4 52 0 55 153 184 777 11 0.8 1 1 1 1
thangavel        638872c 34 2 1 3 4 0 47 164 41 1575 13 0.7 1 1 1 1
thavamani        080746c 49 1 1 3 53 1 67 156 . 1408 13 0.9 2 1 1 1
thirumalai rao   631587c 40 2 1 4 54 0 69 166 49 1129 15 1 1 1 1 1
thirumalaiswami  713509c 36 2 1 2 4 0 58 170 117 1190 14 1 1 1 1 1
thokuli          725480c 35 1 1 3 4 0 65 166 339 2040 12 1 2 2 4 1
uma s            931244b 29 1 1 4 208 0 51 153 103 769 7.9 0.6 2 1 3 1
uma gouri        571826c 36 1 1 2 48 0 64 160 261 1720 12 0.8 1 1 1 1
uma maheshwar rao6423381 40 2 1 4 364 0 65 173 19 660 12 1 2 1 1 1
usha             649355a 36 1 1 2 260 0 51 159 225 2043 11 0.9 . . 1 1
uthayasekhar     459270c 41 2 1 3 24 0 55 163 50 1104 9.6 2 1 1 1 1
vaithinathan     651835c 42 2 1 2 8 2 60 173 296 1478 14 1 2 2 2 1
vanitha          713510c 26 1 1 3 4 0 37 156 56 780 11 0.6 2 2 1 1
vasudevan r      597249c 29 2 1 3 24 4 46 159 74 1406 12 0.8 1 1 1 1
veni             589029c 45 1 1 3 4 0 58 152 101 1040 13 0.7 2 1 1 1
venkatesan       556682c 37 2 1 2 32 1 52 175 56 1402 11 0.8 1 1 2 1
venkateshan b    475976c 43 2 1 3 44 0 52 167 101 2178 13 1 1 1 1 1
venkattammal     562298c 58 1 4 3 104 0 56 148 102 1115 11 0.7 1 1 2 1
venkata sailaja  140923c 31 1 1 3 156 0 61 156 126 789 12 0.7 2 2 1 1
venkateswarulu   554347c 56 2 1 3 4 0 37 158 60 320 12 0.7 1 1 3 1
victor a m       926618b 39 2 1 4 208 0 45 169 30 1020 16 1 1 1 1 1
vijaya           689876c 38 1 1 3 4 0 46 152 130 705 10 0.9 2 2 1 1
vijaykumar bk    434107c 53 2 1 3 52 1 57 168 49 720 9.6 1 2 1 3 1
balasubramanyan.n622642c 45 2 1 4 4 0 58 172 21 736 8.3 1 1 1 1 1
ATT end point reason ADR smoking death followup
2 1 3 0 1 1 4
2 1 1 4 1 1 36
2 2 0 0 2 1 52
1 1 1 3 2 1 7
2 1 1 5 1 1 20
2 2 0 0 2 1 64
2 2 0 0 2 1 52
2 2 0 0 1 1 76
2 2 0 0 2 1 48
2 2 0 0 2 1 56
2 1 1 5 1 1 22
2 1 1 5 1 1 54
2 2 0 0 2 1 14
2 2 0 0 1 1 48
2 2 0 0 2 1 88
2 1 2 0 1 2 24
2 2 0 0 1 1 52
2 2 0 0 2 1 52
1 2 0 0 2 1 96
1 1 2 0 1 2 24
2 2 0 0 1 1 48
2 1 3 0 1 . 8
2 2 0 0 2 1 48
2 2 0 0 2 1 28
2 1 1 1 2 2 2
2 1 1 5 2 1 30
1 2 0 0 2 1 28
1 1 3 0 2 . 4
2 1 1 5 1 1 56
2 1 1 3 1 1 4
2 1 1 1 2 1 2
2 1 2 0 2 1 52
1 1 3 0 1 . 4
2 2 0 0 2 1 48
2 1 1 5 1 1 52
2 2 0 0 2 1 56
2 2 0 0 2 1 48
2 1 1 3 2 1 8
2 2 0 0 2 1 28
2 1 1 4 2 1 48
2 2 0 0 2 1 52
2 2 0 0 1 1 52
2 1 1 4 1 1 44
2 2 0 0 1 1 48
2 1 3 0 1 . 4
2 2 0 0 2 1 48
2 2 0 0 2 1 48
2 2 0 0 2 1 56
2 1 1 3 2 1 8
2 2 0 0 2 1 28
2 2 0 0 2 1 52
2 1 1 4 2 1 48
2 2 0 0 1 1 48
1 2 0 0 1 1 52
2 1 2 0 1 1 6
1 1 1 4 2 1 64
2 1 1 3 2 1 16
2 1 1 3 1 1 36
2 2 0 0 2 1 32
2 1 1 4 1 1 40
2 2 0 0 2 1 48
2 2 0 0 2 1 52
2 1 3 0 1 . 4
2 2 0 0 2 1 32
2 1 4 0 1 2 4
2 1 2 0 2 1 3
2 1 1 5 2 1 24
2 2 0 0 2 1 32
2 1 1 5 2 1 48
2 1 3 0 1 . 9
2 1 3 0 1 . 4
1 2 0 0 2 1 52
2 2 0 0 2 1 68
2 2 0 0 2 1 28
1 2 0 0 2 1 32
2 1 1 6 2 1 32
2 1 1 4 2 1 36
1 1 1 3 2 1 4
2 2 0 0 1 1 52
2 1 3 0 2 . 2
2 2 0 0 2 1 52
2 2 0 0 2 1 48
2 2 0 0 2 1 52
2 2 0 0 2 1 52
1 1 1 4 2 1 56
2 2 0 0 1 1 52
2 2 0 0 2 1 56
2 2 0 0 1 1 44
2 2 0 0 1 1 84
2 2 0 0 2 1 24
2 2 0 0 2 1 68
2 2 0 0 2 1 56
2 1 1 1 2 1 2
2 1 1 3 1 1 8
2 1 1 3 2 1 8
2 2 0 0 2 1 48
2 2 0 0 2 1 28
2 2 0 0 1 1 76
2 1 3 0 1 . 4
2 2 0 0 1 1 48
2 2 0 0 2 1 48
2 2 0 0 2 1 84
2 2 0 0 2 1 52
2 2 0 0 2 1 44
2 2 0 0 2 1 52
2 2 0 0 1 . 96
2 1 3 0 1 . 4
2 2 0 0 1 1 32
2 2 0 0 2 1 48
2 2 0 0 2 1 98
1 2 0 0 2 1 56
1 1 4 0 1 2 12
2 2 0 0 2 1 48
2 1 3 0 1 1 4
2 1 1 4 1 1 51
2 1 1 3 1 1 9
2 1 1 4 1 1 67
2 1 3 0 1 . 4
2 1 1 4 1 1 48
2 2 0 0 2 1 32
2 2 0 0 2 1 34
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